annual report deliver transformational medicine patient lopq rusty cline participate clinical trial new immunotherapy bristolmyer squibbr u work diagnose stage metastatic melanoma rusty cline live horse farm purcellville virginia endure surgery include brain surgery cancer spread ravage body enrol performance brand clinical trial experimental treatment recurrence force leave study geography continued innovation give yervoy ipilimumab recently approve potential treatment option ppprrroooddduuuccctttiiivvviiitttyyy iinn rd investment business disease continue progress development opportunity reflect strength september active tumor stick body not able work execution biopharma strategy consultant essentially wait die not think wait position keep patient long recall parent close friend convince center work enter trial hundred mile home memorial sloan kettere cancer hard develop innovative medicine center new york city stand treatment study nivolumab approve potential transform live people late opdivo certain patient metastatic melanoma seek determine serve immune system activate fight disease fail treatment week scan show percent reduc tion rustys tumor report today tumor shrink percent doctor think s leave probably cancer anymore scar tissue add time start opdivo feel tumor body get small question long go work quickly go work today rusty go work favorite hobby gallop horse ride motor cycle m simply amazing say m simply amazing patient story share annual report depict individual patient response medicine investigational compound representative patient response addition guarantee potential drug indication development receive regulatory approval bristolmyer squibb annual report message chief executive officer indication bristolmyer squibb position continued success right product right plan right people lamberto andreotti chief executive officer exciting year bristolmyer squibb achieve recently early march opdivo approve commercial clinical milestone launch new innovative treatment patient previously treat metastatic product strengthen company meaningful way squamous nonsmall cell lung cancer significant development provide patient population year execute biopharma immunooncology therapy strategy deliver organization globe accelerate evolution diversified specialty hepatitis c biopharma company transform organization lay respect hepatitis c exciting year foundation future growth evident actual cure chronic disease balance approach drive result today build possible evident increasingly competitive tomorrow remain key success good increasingly complex rapidly change area high unmet business good patient medical need requires constantly update approach deliver result receive approval launch daklinza key region world dual regimen daklinza sunvepra revenue billion represent sale address need hcv patient japan combina growth exclude diabete franchise new inline product sale grow performance key market tion daklinza hcv agent market strong country europe immunooncology withdraw new drug application asunaprevir rapidly change treatment landscape hcv conse respect immunooncology groundbreaking year quently receive complete response letter fda sales yervoy metastatic melanoma continue pick daklinza request additional information use momentum reach billion global annual sale combination agent different asunaprevir reason optimistic future prescription delay potential approval phase iii data trend encourage daklinza combination agent use opdivo approve metastatic melanoma address fda request remain confident japan work approval europe able resume review process quickly rest world melanoma lung cancer cardiovascular course year present important clinical datum respect eliquis good year charac opdivo include confirmation survival benefit terize new indication accelerate growth increase pd immune checkpoint inhibitor melanoma lung appreciation product unique differentiate profile cancer opdivo study tumor type trial monotherapy combination eliquis sale grow quarter expect trend medicine anticipate positive datum continue invest increase resource people month come effectively reason eliquis bristolmyers squibb annual report bristolmyer squibb people center patient serve employee possible evolve diversified specialty biopharma company order lead win marketplace good fulfill promise patient customer shareholder make difference people live united common goal source inspiration drive success motivate achieve people job impact live life simple quality life improve wish express gratitude bms china cancer foun dation bring second life boy bristolmyer squibb annual report number new oral anticoagulant prescribe cardiologist newto brand patient japan lay foundation success measure result drive course year ability lie foundation end devote great deal resource people time money building pipeline future addition clinical work immuno oncology hepatitis c mention continue advance new hiv agent latestage development conduct midstage trial fibrotic disease january giovanni caforio enter human trial new agent disease include lupus rheu designate chief executive officer board matoid arthritis cancer thrombosis fibrosis genetically define disease director effective giovanni currently serve chief operating officer pursue academic collaboration business development responsibility lead fully integrate opportunity immunooncology oncology fibrosis genetically define worldwide commercial organization disease underscore fact business development remain companywide function enterprise service global manufacturing supply june priority area align key strategic disease giovanni elect company serve community board director continue pursue communitybase activity giovanni join bristolmyers squibb globe therapeutic area help underserved population vice president general manager italy subsequently assume responsibility benefit place live work southeast europe appoint senior bristolmyer squibb foundation launch new initiative expand vice president european marketing brand access specialty care vulnerable population address commercialization help build company leadership lung cancer epidemic area know tobacco belt immunooncology head high lung cancer incidence mortality country global oncology organization giovanni foundation expand secure future program valuable contribution company strategic focus operational performance prevention care cervical breast cancer woman live hiv role president chief commercial subsaharan africa continue work officer prior join combat hepatitis b c china india fight cancer central eastern bristolmyers squibb giovanni spend year europe help return veteran family united states abbott laboratories number leader ship position giovanni earn md degree respect sustainability bristolmyer squibb rank number university rome join overall corporate responsibility magazine annual list good pharmaceutical industry corporate citizen lead benchmark socially responsible investor stakeholder reflect commitment people high ethical standard progress social environmental sustainability honor strengthen organization privilege lead accelerate evolution important change company begin great company ne completion divestiture diabetes business refocus giovanni caforio md commercial organization optimize global brand key market chief operating officer ceodesignate continue sharpen rd focus specialty product effort significantly expand company biologic manufacturing capacity start expansion plant deven massachusetts recently announce plan build new stateoftheart facility cruiserath ireland bristolmyers squibb annual report message chairman board additionally important leadership change giovanni caforio promote chief operating officer make elect board director recently meaningful difference life select serve chief executive officer patient effective james cornelius chairman end year expand role general counsel promote sandra leung executive proud company vice president financially solid operationally strong launch important initiative company make meaningful difference live patient work focus attention year transform bristolmyer squibb people center biopharma leader lead well result company patient bristolmyer squibb employee video lead well outcome patient picture writing share personal story launch biopharma transformation mean family friend face health challenge new strategy new focus new sense possible combine inspire work company like bristolmyer squibb well big pharma best biotech begin process company dedicate improve people live fundamentally change ask work innovation improvement integration start new conversation bristolmyers squibb accelerate process evolve diversified underscore deep personal connection specialty biopharma company sharpen rd focus work motivate restructure commercial organization host continue success important change support evolution set take good important year future success characterize solid result smart investment result significant lead indication bristolmyer squibb position way multiple therapeutic area make major breakthrough continue success right product immunooncology virology evolve right plan right people organization well meet challenge everchange external environment need everdeserve patient transition chapter bristolmyer squibb story leave position ceo company strong future chairman board director certainly brighter confidence successor lamberto look forward new opportunity miss work andreotti bring energy vision passion position friend colleague jim cornelius retiring board chairman bring role chief executive officer confidence ceo giovanni caforio look forward work new ceo entire bristolmyer squibb family continue build giovannis promotion guarantee smooth transition foundation establish continue deliver patient leadership team set stage promise future company patient thank opportunity serve year lamberto andreotti james cornelius chief executive officer chairman march march bristolmyers squibb annual report bristolmyer squibb business highlight billion global sale include positive result key growth driver include eliquis grow million orencia increase sprycel yervoy grow million hepatitis c franchise combine sale revenue growth key product bmy new commercial model bristolmyer squibb place special nn focus invest grow key brand maintain major franchise key brand deliver strong performance include doubledigit sale growth case total shareholder return outpace market success reflect ability world include dividend wide brand team work cooperatively commercial rd medical group successfully align market global brand message resonate health care provider patient importantly medicine continue deliver real benefit patient rely day worldwide sale united states include puerto rico europe include russia turkey global sale region rest world include japan china include royalty alliancerelate revenue product sell regional commercial organization bristolmyers squibb annual report strategy deliver focus customer need give maximum priority accelerate pipeline development deliver sale growth continue manage cost lamberto andreotti chief executive officer opdivo early march opdivo nivolumab approve treatment patient metastatic squamous nonsmall cell lung cancer nsclc progression prior eliquis therapy opdivo pd therapy demonstrate overall survival previously novel oral anticoagulant treat metastatic squamous nsclc lung prescribe cancer leading cause cancer death nonsmall cell lung cancer cardiologist common type disease accounting percent case read newtobrand patient opdivo company effort immunooncology begin japan approval second opdivo follow approval month early late december patient eliquis global growth unresectable metastatic melanoma disease progression follow yervoy ipilimumab use eliquis apixaban broaden additional approval braf mutation positive braf inhibitor company understand physician need eu treatment prior initial approval opdivo receive payer focus welldevelope reduction risk recurrent venous market approval japan unresectable customerfocuse infrastructure helped opdivo thromboembolism include deep melanoma time drug target launch superior customer experience vein thrombosis dvt pulmonary immune system pd pathway approve service team build embolism eliquis approve world anticipation initial experience yervoy establish use patient nonvalvular atrial fibril approval opdivo company commercial presence marketplace lation prophylaxis dvt follow expand field team include sale medical additional global regulatory filing melanoma affair expert access reimbursement lung cancer currently review hip knee replacement surgery shipment begin day approval unprecedented effort continue explore addition new use eliquis benefit company reach melanoma oncology additional use opdivo multiple tumor increase investment focus health care provider opdivo type monotherapy combination ensure health care provider week interest remain high agent patient understand efficacy safety profile eliquis big mar ket germany japan represent percent sprycel total sale eliquis continue strong growth japan progress continue establish sprycel dasatinib important medicine treatment number novel oral anticoagulant chronic myeloid leukemia cml especially firstline setting differentiate sprycel highly prescribe cardiologist newto competitive marketplace company help physician understand deep fast response brand patient addition positive result simple oncedaily dose food restriction result doubledigit phase iii study announce growth positive longterm efficacy datum secondline use sprycel investigational reversal agent patient continue support predictable manageable effect profile plan study sprycel require reversal antico combination asset company immunooncology portfolio include opdivo agulation effect eliquis major determine certain patient continue sustain clinical response discontinue bleeding event require therapy early study ongoing investigate potential use sprycel certain patient emergency surgery advanced nonsmall cell lung cancer bristolmyer squibb annual report invest billion rd include discovery development new medicine patient orencia sc fully launch kathy take yervoy major market metastatic melanoma world orencia orencia abatacept continue outpace rheumatoid arthritis ra market dollar growth past year result ongoing robust share increase major success surpass billion sale time yervoy additionally orencia sc subcutaneous yervoy ipilimumab break new ground tional setting gain broad formulation fully launch immuno approval reimbursement health major market world add oncology agent demonstrate long authority payer include successful iv formulation publication term survival benefit patient use firstline set avert clinical trial result year advanced melanoma strong finan melanoma patient europe clinical trial datum physician increasingly focus cial performance geography importance datum early use billion global sale part world continue invest orencia patient moderate severe ra yervoy continue generate strong study yervoy new indication potential alter destructive course disease demand community institu generate additional data orencia remain selective tcell mod ulator inhibits costimulation require tcell activation help position orencia firstline new medicine patient biologic treatment option patient moderate severe ra include early rapidly progress past year ing ra poor prognostic factor hepatitis c mid bristolmyers squibb receive approval japan new global campaign help daklinza daclatasvir sunvepra asunaprevir japans interferonfree ribavirinfree alloral combination treat daklinza hepatitis c successfully ment patient genotype chronic hepatitis c hcv infection summer daklinza receive regulatory launch market europe approval eu use combination medicinal product file approval daklinza company pioneer number scientific dis coverie play important role development multiple treatment option hcv patient world treatment time feature high cure rate company turn attention clinical development resource difficulttotreat hcv patient high unmet need new treatment option include patient advance liver cirrhosis represent common genotype liver transplant result infection bristolmyer squibb annual report year ago development project biologic look forward year believe number potentially grow n global manufacturing supply expand biologic capability cultivate innovation biologic bristolmyers squibb increasingly important business development treatment disease company continue expand capa business development remain priority bristolmyer bilitie develop manufacture important new medicine squibb company focus source innovation announce million expansion manufacturing complex internally externally commercial development deven massachusetts nearly double size workforce research platform technology opportunitie support help company expand manufacture potential biologic use nearterm portfolio longterm growth clinical trial construction expect complete bring continue fuel leadership immuno investment billion employee count deven addition oncology evolution diversified specialty biopharma late bristolmyers squibb announce plan construction company variety way discuss new largescale biologic manufacturing facility cruiserath ireland special report begin early create manufacture job job announce additional transaction construction phase new plant build ground expect continue approach publication company exist bulk pharmaceutical manufacturing plant cost annual report facility finalize anticipate comparable invest enter multiple clinical collaboration help generate data ment devens biologic facility year company investigate immunooncology pipeline work announce agreement lonza multiyear expansion exist combination agent include agreement biologic manufacturing agreement include production lonzas facility celldex therapeutic eli lilly ono pharmaceutical portsmouth new hampshire aim meet anticipated demand kyowa hakko kirin prime therapeutic seattle genetic commercial biologics portfolio supplement inhouse manufacturing celgene pharmacyclic janssen novartis incyte university texas md anderson cancer center capability latestage clinical asset announce plan acquire flexus bioscience give right potential immunotherapy focus modulate tumor microenvironment broaden effort discover develop novel approach treat disease variety unique alliance collaboration include immuno oncology cytomx therapeutic prime therapeutic rigel pharmaceutical enhance portfolio acquire right novel asset area interest oncology fibrosis genetically define disease include agreement california institute biomedical research galecto fstar alpha acquisition ipierian inc partner academic research institution identify speed development promise science technolo gy include breakthrough agreement ally mind advance discovery biopharmaceutical innovation lead academic research institution develop time investment venture capital fund expand enhance discovery effort clinical pipeline bristolmyers squibb annual report special report deliver transformational medicine patient bristolmyers squibb annual report evolve business model commercial rd organization share common purpose accelerate innovation area high unmet medical need offer mean ingful differentiate improvement live patient page follow bristolmyer squibb set high bar develop deliver large treatment effect possible focus therapy bestinclass novel mechanism action innovative therapeutic approach transfor mational medical practice biomedical science important patient family evolve business model number principle continue favorable feedback result guide effort build benchmark examine specially train company commercial organization able ambassador include general man deliver marketleading performance ager follow customer bring result innovative science order learn well health care provider patient differently capture institutionaliz enhance external focus help drive ing help competitiveness create value enhance quality customer interaction stakeholder help nece improve governance organizational sary choice allocate right resource structure layer decisionmake appropriately second speed therapy eliminate report relationship patient require emphasis simpli simplified bring market employee fication include streamline governance close customer give individual decisionmake cooperation key responsibility accountability increase efficiency effectiveness speed decisionmake find new well way develop positive result develop imple motivate people improve performance mente increasingly successful global geography function ensure brand strategy harness global meaningful interaction customer capabilitie efficiently new com right strategic operational alignment mercial model make speed market key growth driver therapie speed get drug patient fast development simple emphasizing onebrand identity example france bristolmyer geography reflect squibbs important market general regional difference health care system manager lead innovative initiative reg instance approval daklinza ularly comprehensively obtain feedback daclatasvir eu come launch health care provider promotional campaign share specific interaction company employee geography brainstorm course medical meeting clinical different concept longawaite trial program view response campaign effectively portray bristolmyer squibb annual report speed therapy patient require emphasis simplification include streamline governance decisionmake cooperation key increase efficiency effectiveness longsoughtafter moment patient achieves cure hepatitis c infection successful launch japan daklinza sunvepra asunaprevir alloral interferon ribavirinfree regimen introduce japan hepatitis c infection patient potentially benefit immediately treatment coordinate global effort help experience significant market share increase eliquis apixaban efficacy safety emphasize orencia abatacept focus emerge potential firstline use early active ra disease good growth sprycel dasatinib global team continue execute effectively transform rd important principle guide transform rd organization focus deliver large treatment effect therapy develop possible transform live patient future biomedical science effort include focus breakthrough innovation increase ability speed product patient optimize customer interaction focus good way deliver pipeline product building culture reward talent approach continue depend right organizational alignment therapeutic area asset commercial rd colleague external collaborator institute process make individual accountable potential therapy discovery approval central effort remain ability speed innovative new drug patient require great external focus include well understand scien tific medical business innovation appreciation payer patient need value tap external knowledge establish new line communication well connect senior leadership key academic institution cancer center include center bristolmyers squibb international immunooncology network new center enterprisewide initiative establish rd medical commercial well understand patient need extraordinarily valuable recent lead er meet rd colleague opportunity meet learn colleague mother duchenne muscular dystrophy patient story illustrate breakthrough therapy seek develop bring clinic add real value benefit son quality life insight help rd scientist potentially uncover appropriate endpoint clinical trial gain deep personal appreciation patient journey appreciation extend payer gain insight value ascribe innovative treatment development include relatively small number patient effective treatment case genetically define disease currently investigation kind focus foster additional valuable collaboration bristolmyer squibb annual report lead way immunooncology n e l despite continue advance cancer treatment tumor cancer spread original tumor site chance work longterm survival patient unfortunately remain elusive life daniel potkova fairly recently approval treat metastatic melanoma circumscribe bear raise demonstration significant survival benefit phase iii melanoma live crdoba city second large city argentina daniel job trial yervoy ipilimumab start revolution cancer therapy bring early morning metal worker new hope longterm survival approval yervoy establish come home night spend time pioneer leadership immunooncology transformational oppor adriana wife year son architect daughter teacher tunity cancer patient unleash patient immune system year ago life hard work attack tumor clinical trial demonstrate devotion family suddenly take unex longterm survival advantage proportion patient take yervoy pecte turn feel sick persistent case long year count cough difficulty breathe initial diag nosis pneumonia find month later stage squamous nonsmall today yervoy enjoy broad access world progression prior therapy cell lung cancer tumor right lung wide secondline treatment pd therapy demon lesion leave melanoma continue study strate overall survival previously treat smoker year daniel admits think happen adriana monotherapy combination metastatic squamous nsclc add feel world fall apart number tumor type opdivo work bind checkpoint talk month leave immunooncology asset potentially receptor call pd express surgery option doctor provide longterm survival great activate tcells bodys immune hospital trnsito ccere de allende number patient tumor response foot soldier inhibit recommend enter clinical trial type companys ultimate goal nivolumab new experimental treatment blockade allow immune system bristolmyer squibb seek turn opdivo approve work distinct way patient immune system combat yervoy inhibit checkpoint cancer evaluation tumor company significant progress pathway call ctla lesion shrunk percent deliver second immuno year later disease remain stable oncology drug opdivo nivolumab approval thank trust physician result patient july approval opdivo japan company working date love care family japan unresectable melanoma realize potential opdivo daniel renew sense optimism obtain company partner ono market tumor type quit job result pharmaceutical mark time fda grant breakthrough illness continue rely family pd approve world therapy designation opdivo support daughter return home father difficulty december opdivo approve treatment patient hodgkin lym son accompany doctor visit previously treat metastatic phoma failure autologous stem cell lung cancer diagnosis devastate melanoma reach patient transplant brentuximab clinical trial adriana say teach treasure month fda accept ongoing company success life people love priority review biologic license fully complete regulatory submission application grant opdivo second europe squamous nonsmall cell lung like grandchildren daniel add hope surprised breakthrough therapy designation cancer complete melanoma filing near future early march opdivo receive europe grant accel second approval treatment erate assessment additional regulatory patient metastatic squamous filing potential launch plan nonsmall cell lung cancer nsclc market worldwide bristolmyer squibb annual report teach treasure life people love bristolmyers squibb annual report opdivo good news patient jeffrey weber md medical oncologist moffitt cancer center tampa florida primary focus melanoma patient metastatic disease witness dramatic change past decade treat patient year ago kind desolate landscape metastatic melanoma patient average survival year long time fact immunotherapy work melanoma garner respect today option drug work say change come introduction yervoy ipilimumab immunooncology agent demonstrate long term survival benefit metastatic melanoma new immunotherapy like nivolumab opdivo pd inhibitor study cancer include melanoma demonstrate clinical activity response long duration weber say good news patient recently lead investigator bristolmyer squibbsponsore clinical trial compare nivolumab versus standard chemotherapy patient progress follow treatment yervoy firstline treatment result clearly favor nivolumab report obvious superiority term response rate low toxicity s response brief duration chemotherapy prolong study form basis fda approval opdivo new immunotherapy treatment option certain patient late december story opdivo pd antibodie work clinical study promise compare control arm opdivo fdaapprove multiple checkpoint blockade company monotherapy demonstrate prove superior overall survival com researcher believe pd checkpoint pare standard care year previously treat negative regulator principally affect tumor site metastatic squamous nsclc subsequent fda approval result opdivo potential work indication opdivo base result checkmate broad spectrum activity potentially checkmate well adverse effect profile blockade inhibitor opdivo pd demonstrate efficacy term offer opportunity opdivo elicit durable immune objective response rate pivotal phase iii clinical trial patient response foundational treatment monotherapy advanced melanoma previously treat combination wide range tumor type progress yervoy braf mutation positive braf early clinical trial demonstrate dramatic inhibitor company receive fda approval indication response melanoma lung renal cancer certain late december separately phase iii trial firstline melanoma lymphoma s fda grant fasttrack desig compare opdivo chemotherapy stop early nation opdivo trial lung cancer renal cell carcinoma opdivo show superior survival benefit patient melanoma pursue parallel allow patient comparator arm study receive sequentially order accelerate development delivery opdivo time pd immune checkpoint patient lung cancer prime target lead cancer killer inhibitor demonstrate survival benefit phase iii trial globally result million death opdivo phase ib combination trial yervoy opdivo show indication immunotherapy effect large majority patient receive optimum dose schedule early phase trial opdivo able shrink tumor lung survive twoyear mark half patient alive unprecedented way addition midstage clinical trial threeandahalf year later year ago median checkmate safety profile opdivo squamous nsclc survival advanced melanoma patient year establish phase iii study checkmate evalu ate opdivo versus standard care docetaxel previously finally result announce december small trial patient treat patient metastatic squamous nsclc stop hodgkin lymphoma show percent patient early assessment conduct independent datum treatment option take opdivo experience monitor committee conclude study meet endpoint partial complete response show potential application demonstrate superior overall survival patient receive opdivo immunooncology hematological malignancy bristolmyer squibb annual report patient worldwide process enrol enrol hundreds clinical trial site immunooncology yervoy opdivo bristolmyers squibbs development program opdivo yervoy ipilimumab opdivo nivolumab unprecedented company history new drug develop study potential use multiple tumor type ment breadth potential indication opdivo combination company researcher seeking develop study different tumor type wave immunotherapy include grow separate clinical trial world approxi commitment advance potential treatment option hematologic cancer accelerate development potential mately time include potentially registrational therapy immunooncology make special effort trial nonsmall cell lung cancer melanoma renal cell carci discovery early clinical development achieve noma head neck cancer glioblastoma lymphoma mission speed innovative cancer therapy patient collaboration key discovery science rapidly evolve different aim bring discovery multiple new preclinical component immune system effectively acti immunooncology candidate year vate cancer patient find new option year include additional checkpoint control inhibitor yervoy opdivo member class combination therapie important approach monoclonal antibodie act part establish series collaboration academic immune system inhibit robustly activate institution advance science immunooncology target company seek good possible combination treatment promise preclinical lead advance regimen include opdivo therapy human trial accelerate basis testing monotherapie combination treatment different tumor bristolmyer squibb enter large number type seek expand number patient collaboration include university texas md respond specific immunotherapy treatment anderson cancer center focus leukemia plan bring potential treatment hematologic malignancy intention launch discovery development parallel phase phase ii clinical trial dana farber cancer sequentially test hypothesis time bring institute learn patient treat yervoy safe effective treatment patient soon opdivo cytomx explore multiple immunooncology target company international immunooncology network academic cytomxs proprietary probody discovery platform research institution collaboration important partner identify appropriate patient population company announce new clinical collaboration study potentially effective combination therapy right opdivo potential therapy pharmacyclic janssen drug right patient continue enhance nonhodgkin lymphoma oncology drug novartis understand emerge science nonsmall cell lung cancer antibody kyowa hakko clinical development kirin study ono pharmaceutical kyowa hakko yervoy opdivo investiga kirin advance solid tumor lead candidate tional immunooncology agent early latestage clinical prime therapeutic tumor type ongoing collabora development potential wave tion study opdivo combination drug eli lilly e lotuzumab currently phase iii trial humanize antibody celgene seattle genetics celldex incyte addition direct specific surface protein signal exist partnership innate pharma rockefeller lymphocytic activation moleculef slamf express high level myeloma cell lead immune destruction university ono pharmaceutical dako bristolmyer squibb cancer cell immune system natural killer cell international immunooncology network academic urelumab anticd antibody deliver institution establish costimulatory signal activate enhance functioning early announce plan acquire flexus bio different type immune system cell science right lead ido inhibitor lirilumab bind kir inhibitory pathway broad idotdo discovery program enter design remove block activate immune cell collaboration rigel pharmaceutical portfolio lirilumab study combination yervoy smallmolecule tgf beta receptor kinase inhibitor ido tdo opdivo activate immune system response tgf beta inhibitor immunotherapy think antilag monoclonal antibody inhibit lag sig modulate immediate area surround tumor nale enhance tcell function promote host immune response potentially enhance efficacy enhance immune system ability fight cancer plan tcelltargete therapy explore combination immunotherapy opdivo bristolmyers squibb annual report s take care immunotherapy perfect sense u work judy matusicmullin bethlehem pennsylvania work register nurse year ct scan half year ago reveal ballsized kidney tumor invade inferior vena cava bodys large vein know need surgery immedi ately month later scan find cancer infiltrate lung think know bad year max slip professional mode say advocate professionally child suffer trauma abuse resource find right treatment team judy recall depressed withdraw waste precious time year want live full husband continue work help oncologist fox chase cancer center philadelphia offer position leave clinical trial combine bristolmyer squibb immunotherapy ipilimumab nivolumab s take care immunotherapy perfect sense say follow treatment scan reveal shrinkage spot lung recently scan remain completely clear year good result judy reflects life hold work fulltime not say hold living long sign hot yoga class judy add oncologist remind diagnosis incurable kidney cancer respond positively treatment ve get pumpedup immune system intend force contend universe bristolmyer squibb annual report look future important focus evolution bristolmyer squibbs rd strategy announce late fibrotic disease focus explore disease area high unmet medical need fibrotic disease company bring great value patient company continue characterize advance latestage pipeline current growth driver increase investment buildup potentially immunooncology area significant potential continue focus target deadly scar tissue oncology research include antibody drug conjugate program research effort different organ especially early stage discovery concentrated virology cardiovascular body researcher disease specific focus heart failure immunoscience fibrotic disease seek new new area call genetically define disease gdd program well way inhibit area advance candidate bestinclass potentially trans pathway central formational nature therapeutic area rely mix internal discovery fibrotic disease external collaboration help deliver potential therapy patient area progression include immunoscience immunovirology immunooncology synergy explore learning share science advance oncology virology company unprecedented focus bristolmyer squibb company immunooncology study traditional alloral interferon ribavirinfree oncology agent target cancer cell hepatitis c treatment regimen base directly underway example trial potent pangenotypic nsa complex inhibitor combine sprycel dasatinib chronic myeloid vitro daklinza daclatasvir provide cure leukemia opdivo nivolumab immuno large number patient japan oncology agent explore additional benefit discovery company researcher patient year refining technology help transform way hepatitis c patient company planning enter clinical trial treat new treatment option antibody drug conju company include bristolmyer squibb gates link potent cytotoxic monoclonal today offer possibility cure large num antibody target specific tumor cell ber patient hepatitis c challenge company investigate target therapy remain include help difficulttotreat focus notch inhibitor block powerful hepatitis c patient hiv coinfection pathway promote tumor cell survival advance liver disease common genotype anticxcr monoclonal antibodie certain liver transplant bristolmyers squibb cancer pioneer field focus target population represent great external development key late remain unmet medical need agreement give bristolmyers squibb exclu sive option acquire fstar alpha ltd uk example late datum landmark biotechnology company gain worldwide trial investigate ribavirinfree week regimen right fs lead asset fs novel bristolmyer squibb daklinza gilead human epidermal growth factor receptor sofosbuvir genotype patient second target therapy development breast common genotype worldwide gastric cancer certain patient difficult treat show remarkable result respond resistant current therapy sustain virologic response generally consider bristolmyer squibb annual report research development pipeline immunooncology oncology immunoscience virology cardiovascular phase phase phase phase phase antilag notch inhibitor anticdl antipdl par antagonist lirilumab ulocuplumab anticxcr anticd factor xia inhibitor urelumab antifucosyl gm btk inhibitor eliquis opdivo antiher irak inhibitor phase ii pediatric additional tumor combination sp agonist hiv maturation inhibitor phase ii phase ii phase ii sprycel phase ii registrational ikur inhibitor elotuzumab pediatric lulizumab hiv attachment inhibitor atrial fibrillation ndline multiple myeloma lupus daclatasvir asunaprevir bortezomib combination beclabuvir nsb non nuc opdivo hepatitis c rdline squamous nonsmall cell lung registrational daklinza sunvepra nonhodgkin lymphoma orencia hepatitis c nave follicular lymphoma lupus nephritis reyataz nonhodgkin lymphoma diffuse large bcell lymphoma psoriatic arthritis pediatric powder hodgkin lymphoma rheumatoid arthritis auto injector msi colon nulojix esophageal switch calcineurin inhibitor renal transplant yervoy ovarian adolescent melanoma registrational hiv pipeline elotuzumab stline multiple myeloma bristolmyer squibb early pioneer mechanism action develop bind directly lenalidomide combination company develop directacte antiretroviral arv key site hiv envelope prevent virus relapsedrefractory multiple myeloma treatment patient hivaid treatment attach enter patient main immune lenalidomide combination opdivo help transform hiv death sentence system cd tcells chronic condition january company stline melanoma early pipeline hiv maturation inhibitor ndline squamous nonsmall cell lung receive approval market evotaz atazanavir imply prevent virus ndline nonsquamous nonsmall cobicistat treatment hiv infection adult cell lung combines prove strength reyataz atazanavir mature recognize potential company scientist stline nonsmall cell lung pdl able advance discovery clinic newly approve boost agent cobicistat ndrdline renal cell carcinoma year reduce pill burden sacrifice ndline head neck glioblastoma efficacy battle far potentially offer new option mechanism gastric concern grow number patient action potential longterm safety opdivo yervoy treatment experience resistant tolerability patient new mechanism action stline melanoma arvs remain option increase ability formulate new stline renal cell carcinoma therapie need offer increase safety versatile regimen yervoy tolerability new way suppress virus com stline squamous nonsmall cell lung development potentially new pany researcher hope potentially transform stline small cell lung immunovirologic treatment early study hiv treatment hiv altogether eventually develop adjuvant melanoma patient collaboration nihs aid clinical metastatic melanoma dose optimization functional cure allow immune system trial group evaluate immunotherapy devel prostate posthormonal therapy control hiv use antiretroviral agent ope bristolmyer squibb combination pipeline new approach agent early stage hope advanced hiv attachment inhibitor develop approach combine agent company researcher decade ago help expose virus immune schedule start phase iii trial system activate immune system kill bristolmyer squibb annual report functional cure percent treatmentnave percent treatmentexperience patient relate study continue examine option difficulttotreat patient genetically define fibrotic disease metabolic disease addition discovery effort continue seek potentially transformational therapy hivaid story hepatitis b example company scientist look advance immunovirology eventually increase cure rate phase phase phase hepatitis b potentially deliver functional ccr antagonists antimyostatin mgat inhibitor galectin inhibitor antietau cure hiv current treatment hepatitis b hiv suppress virus replicating phase ii patient drug take phase ii pegfgf lpa antagonist diabete rest patient life lead pulmonary fibrosis resistant strain approach consider ccr antagonist overcome challenge use checkpoint diabetic kidney disease evelopment partnership inhibitor originally develop immunooncology opdivo ono pharmaceutical elotu zumab abbvie lirilumab innate pharma reactivate affect patient immune system sprycel otsuka antiher fstar alpha ltd eliquis pfizer galectin inhibitor trial ongoing study approach hiv galecto biotech ab partnerrun study heart failure cardiovascular disease registrational include investigational drug indicationsformulation approve medicine later bristolmyer squibb make major commitment stage clinical development submit regulatory agency explore area remain significant approval unmet need potential bring important pipeline datum february case transformational therapy patient combat heart failure center focus million people suffer type heart failure europe japan include million number reason hospitalization elderly unfortunately half patient die year initial diagnosis advance slow progression longterm disease modification hard achieve company announce collaboration ambrx develop derivative relaxin nat urally occur hormone aid heart failure patient improve cardiac function advance basic clinical science novel target drug discovery new approach know target expand possibility bristolmyer squibb researcher beginning vigorously explore new avenue internally develop additional external collaboration time company scientist devel ope robust pipeline innovative therapy include earlystage clinical trial important area cardiovascular disease bristolmyers squibb annual report j u novel antiarrhythmic generation antithrom botics antiarrhythmic agent specifically target heart upper work chamber help patient atrial fibrillation need example treatment option antithrombotic agent include factor family able lemon xia anticoagulant par antiplatelet agent lemonade certainly yearold tayjus surampudi potential effective prevent blood clot signifi remarkable family cantly low risk bleed compare exist medicine tayju diagnose believe agent play important role patient duchenne muscular dystrophy dmd rare genetic stroke heart attack disorder involve rapidly worsen muscle weakness loss effective approve therapy immunoscience generally fatal early adulthood initial researcher build learning gain successful treat shock despair family learn transform dismay fear altogether positive ment like orencia abatacept rheumatoid arthritis ra seek entirely new mechanism innovative differentiate start feel hopeless powerless explain aparna mother clinical programmer bristol ra immunesystem disorder goal myers squibb help evaluate clinical trial result offer longlaste remission disease state begin understand react significant unmet need ra include lack response diagnosis start day time exist drug patient lack longterm remission enjoy look cup half patient respond therapy orencia continue study instead half give family new psoriatic arthritis lupus nephritis sense empowerment m eternal optimist tayju not run jump like kid eventually need wheelchair personal care assistance school cognitively fine keep tell people different strength thing tayjus developed abide interest government public policy passion public service seek help fortunate excel debate club representative model congress join patient advocacy group eventually go washington dc help lobby muscular dystrophy research support care fall begin freshman year harvard college say day get acceptance letter simply good day sure head worried manage hour away home time life admit lot help work wonder count fdr role model disability proof major obstacle overcome tayju say people similar situation successful happy life good know company big bristol myers squibb try condition especially company mom work thank advance area medicine people dmd live long treatment today supportive fortunately research develop diseasemodifye therapy underway include bristolmyer squibb start tayjuss journey eyeopener constantly day time tell different different say instead learn emphasize ability enjoy disability independent great feeling day able feel way great day bristolmyer squibb annual report look future immunoscience group devel paucity therapeutic treat fibrotic ope diversified portfolio potential therapy disease science pathophysiology disease case bestinclass end burgeon decade large number new molecular entity treat lupus rheumatoid arthritis lupus academic collaboration aid discovery effort gain nephritis vasculitis autoimmune disorder access disease tissue biomarker database preclinical early human trial animal model fibrosis involve liver kidney lung skin institution medical university translational science well understand individual patient south carolina university michigan university response particular therapy help researcher uncover pennsylvania vanderbilt university mount sinai hospital additional biological molecular pathway target inten cedarssinai medical center additionally bristolmyers squibb sifie focus biomarker identification enable effort enter collaboration california institute s diversified early pipeline feature individual asset biomedical research give company access late target range immunologic pathway cell signal discovery stage asset access novel target discover costimulation affect immune system activation specifically address fibrotic pathway aim match emerge scientific understanding target new pathway series potential therapy genetically define disease gdd clinic variety agent build company estimate monogenic disease leadership costimulation inhibition firstinclass disorder trace single gene defect target bestinclass asset offer opportunity treat wide variety genetically define disease gdd effective therapy unmet need high devel sentinel indication autoimmune disease include immune oping therapy disease rare orphan thrombocytopenia bleed disorder sjogren syndrome attractive potential develop transformational ther characterize dry eye dry mouth rheumatoid apie small short development program arthritis use eventually study lupus irritable announce company intention focus genetically define bowel syndrome ulcerative colitis disease year gdd group work prioritize inclass series anticd costimulation inhibitor potentially disease pursue progressive supranuclear palsy psp target array autoimmune disease remain duchenne muscular dystrophy dmd story great unmet need potentially firstinclass agent btk include initial disease interest inhibitor potentially superior smallmolecule approach cell activation cell signal utilize adaptive design princi psp relatively rare neurodegenerative disease protein ple researcher combine phase iia phase iib single call tau aggregate brain cause gradual deterio trial help speed therapy patient study ration certain brain cell affect patient bestinclass cd antagonist tcell costimulation inhibitor patients europe approve treatment patient die year diagnosis fibrotic disease mid company acquire ipierian californiabase fibrotic disease characterize buildup potentially biotechnology firm focus new treatment tauopathie deadly scar tissue different organ body target include class disease associate pathological aggregation diabetic kidney disease idiopathic pulmonary fibrosis nash tau protein potentially relate tauopathie include fron nonalcoholic fatty liver disease affect percent totemporal dementia alzheimer disease population cause liver scar cirrhosis prevalent psp ipierian lead asset ipn liver cancer researcher seek new well way monoclonal antibody target molecular defect characteristic inhibit pathway central fibrotic disease progression psp cause change patient genome phase trial begin acquisition amira pharmaceutical provide lpa antagonist currently phase ii trial target duchenne muscular dystrophy affect important signal drive fibrosis potential male age result mutate gene therapy ccr antagonist study diabetic kidney x chromosome inherit mother fail produce disease phase ii trial late bristolmyer virtually functional dystrophin protein help muscle squibb enter agreement option acquire galecto cell work properly bristolmyer squibb enter phase trial biotech gain worldwide right lead asset td antimyostatin adnectin preclinically increase pulmonary fibrosis asset galecto focus galectin muscle size block myostatin negatively protein involve type fibrosis regulate skeletal muscle growth bristolmyer squibb annual report corporate responsibility community world bristolmyer squibb day december announce additional million grant focus responsibility corporate citizen promote strengthen communitybase service adolescent live health equity improve health outcome founda aid elderly case elderly live tion expand global access health care global policy hiv care grandchild parent die initiative reduce environmental footprint enhance aid hiv patient suffer comorbiditie include employee safety diversity meet sustainability goal female cancer tuberculosis foundation commit million project bristolmyers squibb foundation focus health disparity region secure future launch bristolmyers squibb foundation launch new philanthropic initiative address inequitie health care lung foundation turn attention relate area target cancer access specialty care underserved population link hiv certain cancer today woman live continue expand effort address cancer hiv africa likely die cervical breast cancer hepatitis b hepatitis c hivaids comorbiditie hiv awareness cervical breast world cancer low potentially deadly consequence cervical cancer relatively unknown region woman lung cancer leading cause cancer death cervical cancer twice likely hivinfecte patient die year diagnosis year hivpositive woman develop cervical cancer year early foundation bridge cancer care initiative woman infect response foundation work address cancer disparity central eastern europe ing raise awareness build support number program expand focus southeastern region primarily partnership pink ribbon red ribbon prrr country high lung cancer incidence mortality coalition lead george w bush institute usaid rates innovative grant program initiate kentucky unaid susan g komen foundation bristolmyers nation hardesthit state disease story squibb foundation found member prrr coalition foundation groundbreake million program seeks expand cervical screening treatment georgia high rate smoke tobacco use breast care education effort underway tanzania georgia million threeyear grant georgia regent swaziland ethiopia cervical cancer leading cause university cancer center seek reduce burden lung cancerrelate death foundation begin collab cancer minority underserved population oration cordaid cuamm doctors africa amref prevention early detection help get proper care ethiopian female cancer initiative initially plan community supportive community service primary target adult intervention densely populate region africanamerican smoker smoker increase effectiveness community outreach place ethiopia foundation work engagetb aid local community health worker africanamerican world health organization global tb programme country faith community subsaharan africa strengthen communitybased care patient tuberculosis tb include hiv foundation second new grantmaking initiative address tb lead killer people live hiv barrier access utilization specialty care service vul nerable population grant partnership center area foundation focus support care highrisk area strengthen capacity safety net provider patient hepatitis b hepatitis c china india deliver specialty care include coordinate expand care december foundation award new grant total collaboration primary care provider specialist million deliver hope program smooth navigation care second area focus devel establish center excellence china oping integrate navigation social support service india replicate achievement hepatitis awareness preven patient clinical appointment educate tion treatment project fund support engage selfcare outside clinic foundation mark veteran day novem africa foundations landmark secure future pro ber announce million new grant support gram celebrate th anniversary provide communitybased program help post veteran family transition care support people live hivaid world aid military civilian life bristolmyer squibb annual report expand global access medicine aid company found member accelerate access initiative collaboration stakeholder seek increase core company mission address unmet access lifesave antiretroviral subsaharan africa medical need specific disease therapeutic area include country severely impact hiv past year special concern part develop world supply million packsbottle zerit stavudine recent number strategy accomplish videx didanosine reyataz atazanavir subsaharan africa announce october daklinza daclatasvir new lowincome country global hiv access program hepatitis c medicine company enter agreement world health organization estimate hepatitis c virus generic medicine manufacturer help infection globally affect million people fight hivaid bristolmyer squibb family community percent company work alongside generic manufacturing infect live low middleincome country recognize licensee helping rapidly learn manufacture atazanavir disproportionate burden disease seek increase use subsaharan africa india demand atazanavir access treatments company announce plan includes project grow ninefold decade primarily tiere pricing licensing tiere pricing daklinza take develop world s company enter consideration nation economic development burden disease license technology transfer agreement medi commitment address hepatitis c addition strategy cine patent pool mpp organization aim expand access include voluntary licensing daclatasvir patent know hiv medicine develop world agreement cover country low middleincome country past year bristolmyer squibb implement sublicense grant company continue access strategy country significantly challenge hiv collaborate mpp important initiative include bring suitable formulation atazanavir pediatric patient advance environmental social sustainability bristolmyer squibb rank corporate responsibility magazine list good corporate citizen rank year company achieve number rank time contribute achievement program reduce energy water consumption emphasis employee diversity safety focus significant expectation supplier increase transparency oncology social worker angie pennington leave review survivorship care option cancer survivor jackie trigg psychoncology services center university kentuckys markey cancer center reduce burden lung cancer kentucky lung cancer kill americans breast prostate prevention control expert assess novel approach colon cancer combine nationwide kentucky lead lung cancer care aim improve survival lung cancer mortality lung cancer incidence develop evaluating intervention enhance quality high rate adult smoker year lung cancer life survivorship individual lung cancer live state address national caregiver problem serve demonstration model state aim create lung cancer survivor studt bristolmyer squibb foundation bridge cancer care say way help primary care provider infor program support firstofitskind initiative encourage mation need offer highquality lung cancer control early detection treatment lung cancer combine population include evidencebase tobacco treatment provider education patient support million method program seeks reduce stigma threeyear grant attach lung cancer patient see dr jamie studts university kentucky direct responsible disease finally train assistance kentucky lead collaborative bring provide ensure highquality lung cancer interdisciplinary team community partner lung cancer screening deliver screening site statewide cid bristolmyer squibb annual report fourth year row bristolmyer squibb million mmbtus energy reduce co name leader climate change transparency list emission million kilogram company sp climate disclosure leadership index depth complete energyrelated project generate annual quality climate change datum give investor average saving million global marketplace carbon disclosure project complete progress sustainability project global environmental disclosure system company significant portfolio solar cogeneration project hopewell nj facility recently bristolmyer squibb receive usepa energy instal solar energy system atop parking deck produce star certify building label building plainsboro energy power home reduce greenhouse nj facility complete energy assessment major gas emission ton year company use facility example energy minimization manat puerto portion energy remainder provide regional rico chill water optimization project annually save power grid new cogeneration system expect reduce carbon emission ton year companywide energy saving reduce greenhouse gas emission tanzania clean water project metric ton equivalent remove fact child age die year passenger vehicle road waterrelate disease tanzania palpable evidence urgent need improve sanitary condition significant progress continue improvement package thank grant bristolmyers squibb foundation logistics supplychain sustainability example year develop cooperation company environment health logistic team work commercial distri safety sustainability department people bution partner consolidate separate distribution center rural tanzania benefit expansion global sustainable company deliver product partnership gsps effort improve access clean safe drinking water countryside market central location save million transport cost annually significantly reduce carbon emission funding help gsp install hydraid biosand water filter rural village ninemonth period include reduce environmental impact product package dozen local primary secondary school reduce possible high priority japan size biological contamination produce water safe orencia abatacept carton reduce percent drink food preparation personal hygiene sanitation certain market outer paperboard carton reyataz past month gsp begin deliver simple lightweight filter school disseminate eliminate reusable coldchain packaging ve reduce awardwinne curriculum train teacher student woman landfill waste australia ton year earn special rec key community leader build local capacity encourage ognition australian packaging covenant new supplier healthy habit home clinic school tanzanias president share ecofriendly goal expect incorporate similar hope use installation filter school help student feature product design well understand linkage science technology step create laboratory school building company make positive impact building design bristolmyer squibb zymogenetics rd subsidiary seattle washington biologic develop elite group laboratory earn green building council leadership energy environment design lee silver certification exist building facility focus water energy efficiency indoor air quality green cleaning ensure durable good purchase facility sustainable system upgrade seattle site help reduce water electricity usage percent natural gas usage percent effort seek ensure safest working environment company employee strengthen safety culture capability global manufacturing supply deploy dupont safety training observation program stop behavioral safety training program help supervisor employee identify eliminate unsafe work practice condition man ufacture facility globally participate bristolmyer squibb financial report managements discussion analysis report management financial condition result operation control procedure quantitative qualitative disclosure market risk report independent register public accounting firm consolidated financial statement performance graph note consolidated financial statement fiveyear financial summary bristolmyer squibb management discussion analysis financial condition result operation executive summary bristolmyers squibb company refer bristolmyer squibb bms company global specialty biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease continue evolve business lead diversified specialty biopharma company evolution accelerate result diabete business divestiture continue focus certain therapeutic area include immunooncology follow provide brief summary certain key event discuss detail report opdivo approve japan unresectable metastatic melanoma announce positive result certain study melanoma lung hodgkin lymphoma renal cell carcinoma clinical collaboration enter seek opportunity strategically combine opdivo target agent dozen tumor type eliquis obtain important label extension receive regulatory approval hepatitis c franchise include daklinza eu dual regimen daklinza sunvepra japan business development transaction complete advance pipeline therapeutic area include fibrosis genetically define disease expand biologic manufacturing capacity deven massachusetts announce plan build new facility ireland revenue decrease result diabete business divestiture exclusivity loss expiration right partially offset high sale key product include recently launch product certain market focus optimize global brand key market accelerate growth key product eliquis sale increase million follow global launch yervoy sale increase million continue penetration communitybase set line indication improve access internationally hepatitis c franchise sale million follow launch japan certain eu country expect product continue grow orencia sprycel recently launch opdivo partially offset revenue reduction result expiration certain right pertain abilify royalty alliance agreement exclusivity loss baraclude change foreign currency rate high pension research development relate charge contribute reduction gaap eps nongaap ep increase proceed diabetes divestiture increase cash marketable security billion highlight follow table summarize financial information year end december dollar million share datum total revenue total expense earning income taxis provision forbenefit income taxis effective taxbenefit rate net earning attributable bms gaap nongaap dilute earning share gaap nongaap cash cash equivalent marketable security nongaap financial measure include nongaap earning relate eps information adjust exclude specify item represent certain cost expense gain loss item impact comparability financial result detail list specify item information reconciliation nongaap financial measure nongaap financial measure annual report strategy continue transform bms lead diversified specialty biopharma company focus exclusively discover develop deliver innovative medicine address unmet medical need continue evolve drive fundamental objective grow market product progress pipeline develop new medicine follow core therapeutic area oncology virology immunooncology specialty cardiovascular disease fibrosis genetically define disease pioneer innovative medicine area immunooncology unlock bodys immune system battle cancer yervoy ipilimumab immunooncology agent introduce treatment metastatic melanoma announce multiple regulatory milestone european union eu opdivo nivolumab investigational pd immune checkpoint inhibitor continue invest significantly deep pipeline innovative medicine cover broad array cancer enter collaboration agreement research develop opdivo approve investigational oncology agent combination regiment evolve commercial model grow market product portfolio manner consistent overall strategy oncology building success yervoy yield revenue approximately billion product sprycel dasatinib erbitux cetuximab oncology remain strongly commit eliquis apixaban launch globally alliance pfizer inc pfizer eliquis receive regulatory approval eu treatment deep vein thrombosis dvt pulmonary embolism pe adult related indication continue support key brand virology franchise reyataz atazanavir sulfate baraclude entecavir achieve regulatory milestone hepatitis c portfolio launch daklinza daclatasvir sunvepra asunaprevir dual regimen japan launch daklinza eu addition continue invest orencia abatacept account approximately billion revenue look ahead continue implement biopharma strategy drive growth key brand execute new product launch invest pipeline focus prioritize market increase investment biologic manufacturing capability maintain culture continuous improvement pursue discipline capital allocation include business development product pipeline development rd program manage portfolio basis early discovery latestage development continually evaluate portfolio ensure appropriate balance earlystage latestage program support future growth rd program phase iii development consider significant program constitute latestage development pipeline development program include investigational compound phase iii development initial indication market product phase iii development additional indication formulation spend program represent approximately annual rd expense individual investigational compound market product represent rd expense year latestage development program potentially impact revenue earning year expect latestage development program market follow recent significant development market product latestage pipeline opdivo nivolumab fully human monoclonal antibody bind program death receptor pd nkt cell investigate anticancer treatment opdivo alliance ono unresectable inoperable metastatic advanced melanoma december company announce food drug administration fda approve opdivo treatment unresectable metastatic melanoma disease progression follow yervoy ipilimumab braf v mutation positive braf inhibitor indication approve accelerate approval base tumor response rate durability response continue approval indication contingent verification description clinical benefit confirmatory trial november company announce result checkmate phase iii randomize double blind study compare opdivo chemotherapy dacarbazine dtic patient treatment nave braf wildtype advanced melanoma n study meet primary endpoint overall survival os median os reach opdivo versus month dtic oneyear survival rate opdivo versus dtic decrease risk death patient treat opdivo hazard ratio death hr p survival advantage observe opdivo treat patient pdl positive pdl negative patient september company announce result checkmate phase iii randomize control openlabel study opdivo versus investigator choice chemotherapy icc patient advanced melanoma previously treat yervoy base plan interim analysis coprimary endpoint objective response rate ci opdivo arm n ci icc reference arm n patient month follow bristolmyer squibb september european medicines agency ema validate review marketing authorization application maa opdivo advanced melanoma application grant accelerate assessment emas committee medicinal product human use chmp june company announce randomize blind comparative phase iii study evaluate opdivo versus dacarbazine patient previously untreate braf wildtype advanced melanoma checkmate stop early analysis conduct independent datum monitor committee dmc show evidence superior os patient receive opdivo compare control arm patient trial unblinde allow cross opdivo june company announce follow result phase ib doserange trial evaluate safety activity combination regimen opdivo yervoy give concurrently sequentially patient advance melanoma study n additional year follow cohort receive concurrent combination regimen opdivo mgkg plus yervoy mgkg n oneyear os rate twoyear os rate dose ongoing phase ii phase iii melanoma trial checkmate new safety signal report concurrent combination cohort additional follow n company announce update survival datum advanced melanoma cohort n expand phase ib doserange study opdivo administer single agent study result show sustained activity heavily pre treat patient population define threeyear survival rate respectively dose cohort nonsmall cell lung cancer january company announce openlabel randomize phase iii study evaluate opdivo versus docetaxel previously treat patient advance squamous cell nonsmall cell lung cancer nsclc stop early assessment conduct independent dmc conclude study meet endpoint demonstrate superior os patient receive opdivo compare control arm company share datum time indicate survival advantage antipd immune checkpoint inhibitor lung cancer health authority october company announce result checkmate phase ii singlearm openlabel study opdivo administer single agent patient advance squamous cell nsclc progress prior systemic treatment receive prior therapy n approximately month minimum follow objective response rate studys primary endpoint ci assess independent review committee irc recist criterion median duration response reach estimate oneyear survival rate ci median overall survival mos months ci september ema validate review maa opdivo advance squamous cell nsclc complete regulatory submission pd immune checkpoint inhibitor tumor type company announce result phase ib study evaluate safety efficacy opdivo single agent patient advance squamous cell nsclc previously treat study phase ib study evaluate opdivo single agent chemotherapynave patient checkmate study twoyear survival rate dose n previouslytreate patient receive opdivo single agent high patient receive mg kg dose n checkmate overall response rate pdl positive tumor pdl negative tumor chemotherapynave patient receive opdivo single agent n type treatmentrelate adverse event saes checkmate consistent opdivo trial patient experience grade treatment relate saes checkmate multiarm study evaluate opdivo monotherapy combination agent april company meet fda result study evaluate opdivo thirdline squamous cell nsclc initiate roll submission indication base study company complete rolling submission december indication december company announce result cohort patient ongoing phase ib trial checkmate evaluate opdivo patient relapse refractory hematological malignancy n result show high level response patient relapse refractory classical hodgkin lymphoma hl overall response rate n stable disease n company announce fda grant opdivo breakthrough therapy designation treatment patient hl failure autologous stem cell transplant brentuximab annual report company announce result phase ii phase ib study opdivo patient advance metastatic renal cell carcinoma phase ii checkmate doserange trial n overall response rate opdivo single agent range oneyear survival rate range patient receive prior antiangiogenic treatment phase ib checkmate trial overall response rate investigational combination regimen opdivo yervoy n range week progression free survival rate range previously treat treatmentnave patient hepatitis c portfolio daklinza daclatasvir dcv nsa replication complex inhibitor sunvepra asunaprevir asv ns protease inhibitor beclabuvir bcv nsb nonnucleoside polymerase inhibitor development february fda notify company intention rescind breakthrough therapy designation certain genotype hepatitis c regimen relate daclatasvir investigational bms therapy impact current submissionresubmission timetable new drug application daclatasvir combination antiviral agent treatment hepatitis c november company announce fda issue complete response letter crl new drug application nda dcv combination agent treatment hepatitis c virus hcv initial dcv nda submit fda focus use combination asv give withdrawal asv bms october fda request additional datum dcv combination antiviral agent treatment hcv bms discussion fda scope data november company announce result unity trial program investigate week regimen alloral dcvtrio regimen fixeddose combination dcv asv bcv dcvtrio broad range patient genotype hcv primary endpoint study percentage patient achieve cure define hcv rnalloq tdtnd posttreatment week treatmentnave treatmentexperience patient unity study evaluate cirrhotic patient week regimen dcvtrio show sustained virologic response week treatment svr treatmentnave treatmentexperience cirrhotic patient ribavirin rbv treatmentnave treatmentexperience cirrhotic patient rbv november company announce result landmark ally trial investigate ribavirinfree week regimen dcv combination sofosbuvir sof genotype hcv patient population emerge difficult treat result study show sustained virologic response week treatment svr treatmentnave treatmentexperience patient sof product gilead sciences inc gilead october company announce pursue fda approval dual regimen dcv asv treatment hcv genotype b patient withdraw nda asunaprevir company continue pursue fda approval dcv currently investigate globally multiple treatment regimen hcv patient high unmet need august company announce european commission ec approve daklinza use combination medicinal product genotype treatment chronic hcv infection adult daklinza combination sof alloral interferonfree regiman provide cure rate clinical trial include patient advance liver disease genotype previously fail treatment protease inhibitor daklinza nsa complex inhibitor approve eu available use combination medicinal product provide short treatment duration week compare week treatment interferon ribavirinbase regimen july company announce japanese ministry health labor welfare approve daklinza sunvepra new hcv treatment lead cure patient japan currently treatment option daklinza sunvepra dual regimen japan alloral interferon ribavirinfree treatment regimen patient genotype chronic hcv infection include compensate cirrhosis indication daklinza sunvepra japan patient ineligible intolerant interferonbase therapy patient fail respond interferonbase therapy elotuzumab humanized monoclonal antibody investigate anticancer treatment elotuzumab alliance abbvie inc abbvie company abbvie announce fda grant elotuzumab breakthrough therapy designation use combination lenalidomide dexamethasone treatment multiple myeloma patient receive prior therapy designation base finding randomize phase ii openlabel study evaluate dose level elotuzumab combination lenalidomide lowdose dexamethasone previouslytreate patient include mgkg dose study phase iii trial bristolmyers squibb reyataz atazanavir sulfate franchise protease inhibitor treatment human immunodeficiency virus hiv include reyataz include combination therapy evotaz atazanavir mg cobicistat mg evotaz alliance gilead january company announce fda approve evotaz tablet treatment hiv infection adult daily single tablet drug regiman combine reyataz tybost sustiva efavirenz franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg product sell joint venture gilead october company announce successfully resolve outstanding patent litigation relate efavirenz active ingredient contain sustiva atripla loss exclusivity efavirenz expect occur december yervoy ipilimumab monoclonal antibody treatment patient unresectable metastatic melanoma june company announce result phase iii randomize double blind study demonstrate yervoy mg kg significantly improve recurrencefree survival rfs length time recurrence death versus placebo patient stage melanoma high risk recurrence follow complete surgical resection adjuvant set reduction risk recurrence death observe year estimate patient treat yervoy free disease recurrence compare estimate patient placebo median rfs months yervoy versus month placebo median followup year orencia abatacept fusion protein indicate adult patient moderate severe active rheumatoid arthritis ra indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular juvenile idiopathic arthritis november company announce result new subanalyse phase iiib avert assess early rheumatoid arthritis treatment trial investigate use orencia plus methotrexate mtx biologic mtxnave citrullinate protein ccppositive early moderate severe ra patient firstline therapy orencia combination mtx result patient early ra achieve significantly high rate stringent measure remission include percent patient achieve booleandefine remission percent patient achieve cdai sdaidefined remission month versus patient mtx percent percent percent respectively p measure june company announce release new datum phase iiib avert trial show orencia combination mtx achieve significantly high rate dasdefine remission month treatment standard care agent mtx biologic mtxnave patient early active ra eliquis apixaban oral factor xa inhibitor target stroke prevention nonvalvular atrial fibrillation nvaf prevention treatment venous thromboembolic vte disorder eliquis alliance pfizer november company pfizer portola pharmaceuticals announce result phase iii annexaa andexanet alfa novel antidote anticoagulant effect fxa inhibitor apixaban studies andexanet alfa produce rapid nearly complete reversal approximately percent p value anticoagulant effect eliquis healthy volunteer age august company pfizer announce result prespecifie secondary analysis eliquis phase iii amplify ext trial apixaban initial management pulmonary embolism deep vein thrombosis firstline therapy extend treatment analysis evaluate clinical demographic predictor allcause hospitalization patient vte include treatment dvt pe result analysis demonstrate month extend treatment vte eliquis significantly reduce risk hospitalization versus placebo august company pfizer announce fda approve supplemental new drug application snda eliquis treatment dvt pe reduction risk recurrent dvt pe follow initial therapy july company pfizer announce ec approve eliquis treatment dvt pe adult july company pfizer announce patient enrol phase iv clinical trial call emanate assess effectiveness safety eliquis patient nvaf undergo cardioversion annual report march company pfizer announce result prespecifie subanalysis phase iii aristotle trial assess effect blood pressure control outcome study show result stroke risk reduction eliquis versus warfarin consistent overall aristotle study result demonstrate eliquis reduce stroke systemic embolism cause few major bleed event reduce allcause mortality compare warfarin regardless blood pressure control result show poor blood pressure control associate substantially high risk stroke systemic embolism independent eliquis warfarin treatment march company pfizer announce fda approve snda eliquis prophylaxis deep vein thrombosis lead pe patient undergo hip knee replacement surgery february company pfizer announce result prespecifie subanalysis phase iii aristotle trial relation patient age aristotle design evaluate efficacy safety eliquis compare warfarin reduce risk stroke systemic embolism patient nvaf subanalysis find consistent result age group reduce risk stroke systemic embolism reduce risk allcause death few bleed event eliquis versus warfarin owe high risk old age age old absolute benefit patient nvaf great eliquis old population result operation total revenue composition change revenue follow year end december vs vs total revenue analysis change analysis change total foreign total foreign dollar million change volume price exchange change volume price exchange united states europe rest world othera na na na na na na total revenue include royalty alliancerelate revenue product sell regional commercial organization change excess single country outside contribute total revenue period present general business seasonal change revenue attribute volume result diabetes business divestiture february partially offset increase demand eliquis yervoy sprycel change revenue attribute volume result exclusivity loss plavix avaproavalide march partially offset increase demand sprycel yervoy amylinrelate diabetes product revenue follow completion acquisition august change revenue attribute price result high average net selling price abilify aripiprazole key product change revenue attribute price result reduction share abilify revenue impact offset high average net selling price abilify key product key product discussion total revenue key product change europe revenues attribute volume result expiration eu commercialization rights abilify june diabete business divestiture february loss exclusivity sustiva november partially offset increase demand eliquis yervoy orencia launch daklinza certain eu country change europe revenues attribute volume result increase demand key product particularly yervoy sprycel orencia amylin relate product revenue follow transition nonus operation second quarter partially offset restructure sanofi agreement item financial statementsnote alliance discussion revenue period continue negatively impact fiscal challenge european country healthcare payer include government agency reduce expect continue reduce healthcare cost action directly indirectly impose additional price reduction measure include mandatory discount rebate restrictive measure change europe revenues attribute price result reduction atripla revenue sharing average net selling price bristolmyer squibb change rest world revenue attribute volume result increase demand key product particularly eliquis yervoy sprycel launch daklinza sunvepra japan partially offset diabetes business divestiture change rest world revenue attribute volume result growth key product partially offset restructure sanofi agreement generic competition mature brand period impact unfavorable foreign exchange primarily japan revenue increase period high royalty mature brand overthecounter product alliance diabete product supply sale certain alliance revenue expect decline approximately million continue decline expiration relate royalty alliance agreement item financial statementsnote alliance discussion alliance recognize revenue net grosstonet adjustment describe critical accounting policy share certain abilify atripla revenue reflect net grosstonet adjustment alliance revenue present grosstonet adjustment table share abilify atripla grosstonet adjustment approximately billion billion billion change grosstonet adjustment impact additional rebate discount require healthcare reform reduction share abilify revenue activity end reserve balance significant category grosstonet adjustment follow manage healthcare chargeback rebate related government cash contract medicaid sale dollar million program discount discount rebate return adjustment total balance january provision relate sale current period prior period return payment assetsrelate liability heldforsale impact foreign currency translation balance december provision relate sale current period prior period return payment impact foreign currency translation balance december reconciliation gross product sale net product sale significant category grosstonet adjustment follow year end december dollar millions gross product sale grosstonet adjustment chargeback related government program cash discount manage healthcare rebate contract discount medicaid rebate sale return adjustment total grosstonet adjustment net product sale annual report grosstonet adjustment rate primarily function change revenue mix contractual legislative discount rebate grosstonet adjustment increase decrease chargeback relate government program cash discount decrease result low plavix sale follow loss exclusivity manage healthcare rebate contract discount decrease follow diabetes business divestiture february partially offset high eliquis sale manage healthcare rebate contract discount increase primarily higher amylinrelate sale medicaid rebate increase incremental discount price increase take excess inflation high program participation rate high provision reversal relate sale prior period medicaid rebates decrease low plavix sale high provision reversal relate sale prior period sale return decrease additional reserve establish follow plavix avaproavalide loss exclusivity sale return reserve plavix avaproavalide million million december respectively determine consider factor include estimate inventory level distribution channel accordance company policy product eligible return month prior month product expiration adjustment require future result actual return expect occur adjustment increase primarily high government rebate nonus market bristolmyers squibb product revenue change attributable year end december change foreign exchange dollar million vs vs vs vs virology baraclude entecavir nonus hepatitis c franchise daclatasvir asunaprevir na na na na nonus na na na na reyataz atazanavir sulfate nonus sustiva efavirenz franchise nonus oncology erbitux cetuximab na nonus na opdivo nivolumab na na na na na na nonus na na na na sprycel dasatinib nonus yervoy ipilimumab nonus neuroscience abilify aripiprazole nonus immunoscience orencia abatacept nonus cardiovascular eliquis apixaban na na na nonus na na diabetes alliance nonus mature product nonus change excess annual report baraclude oral antiviral agent treatment chronic hepatitis b revenue decrease launch generic entecavir teva pharmaceutical industries ltd september revenue increase high average net selling price demand international revenue increase high demand hepatitis c franchise daklinza nsa replication complex inhibitor sunvepra ns protease inhibitor daklinza launch germany august certain eu country september daklinza sunvepra dual regimen launch japan september reyataz protease inhibitor treatment hiv revenue decrease period low demand result competitor product international revenue decrease time government purchase certain country low demand result competitor product international revenue increase high demand time government purchase certain country period impact unfavorable foreign exchange sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla product sell alliance gilead revenue increase period high average net selling price partially offset low demand international revenue decrease sustiva loss exclusivity europe november negatively impact demand average net selling price atripla revenue sharing erbitux monoclonal antibody design exclusively target block epidermal growth factor receptor express surface certain cancer cell multiple tumor type normal cell currently indicate use treatment patient certain type metastatic colorectal cancer squamous cell carcinoma head neck erbitux alliance lilly revenue remain flat period opdivo fully human monoclonal antibody bind pd nkt cell investigate anticancer treatment opdivo alliance ono opdivo launch december japan september treatment unresectable metastatic melanoma sprycel oral inhibitor multiple tyrosine kinase indicate firstline treatment adult philadelphia chromosome positive chronic myeloid leukemia chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib meslylate sprycel alliance otsuka pharmaceutical co ltd otsuka revenue increase period primarily high demand international revenue increase period primarily high demand partially offset unfavorable foreign exchange yervoy monoclonal antibody treatment patient unresectable metastatic melanoma revenue increase period high demand revenue favorably impact recognition million revenue previously defer international revenue increase period high demand abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder alliance otsuka revenue increase primarily high average net selling price partially offset reduction share abilify revenue revenue decrease reduction contractual share revenue partially offset high average net selling price commercialization right abilify expire april expect loss product exclusivity result significant decline abilify revenue international revenue decrease primarily expiration eu commercialization rights june otsuka principal end customer sale certain market international revenue increase primarily high demand bristolmyer squibb orencia fusion protein indicate adult patient moderate severe active ra indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular juvenile idiopathic arthritis revenue increase period primarily high average net selling price high demand subcutaneous formulation international revenue increase period primarily high demand subcutaneous formulation partially offset unfavorable foreign exchange eliquis oral factor xa inhibitor target stroke prevention nonvalvular atrial fibrillation prevention treatment vte disorder eliquis alliance pfizer international revenue continue increase follow launch major market reduction risk stroke systemic embolism patient nvaf treatment vte diabetes alliance include bydureon byetta farxiga onglyzakombiglyze myalept symlin alliance astrazeneca revenue decrease diabetes business divestiture february revenue increase amylin acquisition august high demand average net selling price onglyzakombiglyze item financial statementsnote alliance discussion mature product include product include lose exclusivity major market overthe counter brand royaltyrelate revenue revenue decrease period continued generic erosion certain product include plavix avapro avalide lose exclusivity result low revenue billion international revenue remain relatively flat continue generic erosion product offset high revenue attribute certain alliance international revenue impact change attribute restructure sanofi agreement avaproavalide plavix item financial statementsnote alliance discussion revenue expect significantly decline reduction approximately million related expiration certain royalty alliance agreement continue decline mature product estimate endus demand pursuant securities exchange commission sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject de minimis exception estimate level inventory distribution channel excess month hand follow product material result operation date indicate reyataz month inventory hand internationally september compare month inventory hand june level inventory exceed month hand primarily government purchasing pattern brazil efferalgan analgesic product sell principally europe month inventory hand internationally september june level inventory hand primarily order pattern pharmacist france generally determine month hand estimate inventory level product hand movement provide large wholesaler account approximately total gross sale product factor influence estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process business outside significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely direct customer product level inventory ultimate patientconsumer demand outmovement datum exist available develop variety methodology estimate datum include factor historical sale direct customer thirdparty market research datum relate prescription trend endus demand accordingly rely variety method estimate direct customer product level inventory calculate month hand factor affect estimate include generic competition seasonality product direct customer purchase light price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior file annual report disclose product level inventory excess month hand expect demand subject de minimis exception quarterly report form q annual report expense change dollar million vs vs cost product sell marketing sell administrative advertising product promotion research development impairment charge bms intangible asset incomeexpense total expense change excess cost product sell cost product sell include material cost internal labor overhead own manufacturing site thirdparty processing cost supply chain cost settlement foreign currency forward contract hedge forecast intercompany inventory purchase transaction essentially cost manage global manufacturing supply organization cost product include royalty profit sharing attribute license product alliance amortization acquire develop technology cost business combination milestone payment occur regulatory approval cost product sell vary period result product mix particularly result royalty profit sharing expense connection alliance price inflation cost attribute rationalization manufacturing site result accelerated depreciation impairment charge strand cost addition change foreign currency provide volatility certain cost denominate foreign currency cost product sell percentage total revenue cost product sell decrease primarily diabetes business divestiture billion partially offset high eliquis profit sharing pfizer accelerate depreciation certain manufacturing facility cost product sell remain relatively flat high profit sharing expense high net amortization cost follow amylin acquisition offset low royalty follow loss exclusivity plavix avaproavalide low impairment charge impairment charge million recognize include million relate continued competitive pricing pressure reduction undiscounte project cash flow carrying value develop technology intangible asset remain million impairment charge relate abandonment manufacturing facility result outsource manufacturing process marketing sell administrative marketing selling administrative expense include salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost expense attribute product manufacturing cost research development expense expense manage regional commercialization organization global corporate organization finance legal information technology human resource certain expense share alliance partner base contractual agreement marketing sell administrative expense remain relatively flat increase salesrelated activity support eliquis yervoy opdivo hepatitis c franchise high variable employee compensation additional brand prescription drug fee offset low expense follow diabetes business divestiture million july irs issue final rule regulation brand prescription drug fee annual nontaxdeductible fee payable federal government affordable care act base allocation company market share brand prescription drug sell certain government program prior year final rule accelerate bms industry participant expense recognition criterion fee obligation year fee pay year market share allocate fee determine result additional year expense recognize quarter include million marketing selling administrative expense million expense final rule regulation change time annual fee pay marketing selling administrative expense decrease accelerate vest amylin stock option restrict stock unit million lower brand prescription drug fee reduction sale relate activity certain product coincide respective lifecycle partially offset high spending support launch new key product additional spending follow amylin acquisition bristolmyers squibb advertising product promotion advertising product promotion expense include medium sample direct consumer program advertise product promotion expense decrease follow diabetes business divestiture advertising product promotion expense increase newly launch product research development research development expense include salary benefit cost thirdparty grant fee pay clinical research organization supply facility cost research development expense include cost discovery research preclinical development early lateclinical development drug formulation clinical trial medical support market product proportionate allocation enterprisewide cost facility information technology employee stock compensation cost appropriate cost upfront licensing fee relate payment achievement regulatory contractual milestone include certain expense share alliance partner base contractual agreement expense attribute development activity manage global research development organization approximately billion billion billion remainder attribute preclinical research activity expense vary period number reason include time upfront milestone licensing payment research development expense increase million iprd impairment charge include million peginterferon lambda high variable employee compensation clinical development cost million charge acquisition ipierian upfront contingent milestone payment million item financial statement note acquisition note goodwill intangible asset information research development expense decrease prior year charge include million iprd impairment charge million accelerate vest amylin stock option restrict stock unit million upfront milestone licensing payment partially offset additional cost follow amylin acquisition high clinical grant spending impairment charge bms intangible asset billion impairment charge recognize development bm inx compound acquire acquisition inhibitex treat hcv discontinued interest patient safety item financial statement note goodwill intangible asset information intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment critical accounting policy discussion incomeexpense year end december dollar million interest expense investment income provision restructure litigation chargesrecoverie equity net income affiliate outlicense intangible asset impairment gain sale product line business asset alliance licensing income pension curtailment settlement special termination benefit incomeexpense provision restructure primarily attributable employee termination benefit result workforce reduction manufacturing sell administrative research development personnel geographic region additional charge approximately million related specialty care transformation initiative expect item financial statementsnote restructure discussion litigation chargesrecoverie include million share apotex damage award concern plavix annual report equity net income affiliate primarily related international partnership sanofi europe asia decrease period result restructure sanofi agreement continues negatively impact generic competition plavix europe asia outlicense intangible asset impairment charge relate certain asset acquire medarex zymogenetics inc acquisition result unfavorable clinical trial result andor abandonment program gain sale product line business asset result primarily diabete business divestiture item financial statementsnote alliance details alliance licensing income include royalty transitional service fee amortization defer income attribute development agreement result diabete business divestiture decrease plavix sale result low development royalty owe sanofi royalty receive sanofi europe asia present revenue begin result restructure sanofi agreement item financial statementsnote alliance discussion pension settlement charge million recognize follow purchase group annuity contract prudential december additional pension settlement charge recognize determine annual lump sum payment exceed annual interest service cost certain pension plan include primary pension plan charge include acceleration portion unrecognize actuarial loss similar charge occur future item financial statementsnote pension postretirement postemployment liability detail income taxis dollar million earning income taxis provision forbenefit income taxis effective taxbenefit rate historically effective income tax rate low statutory rate decision indefinitely reinvest earning certain manufacturing operation ireland puerto rico favorable tax rate ireland puerto rico grant schedule expire prior increase effective tax rate result unfavorable earning mix high low tax jurisdiction retroactive reinstatement rd credit legislation additional tax reserve transfer pricing matter partially offset high tax benefit attribute specify item minimal income taxis attribute diabetes business divestiture gain capital loss deduction sale amylin share tax basis difference result primarily allocate goodwill amylin defer taxis tax benefit attribute research development charge result acquisition ipierian change effective tax rate result million tax benefit attribute capital loss deduction result tax insolvency inhibitex impact deduction reduce effective tax rate percentage point change result low discrete tax benefit attribute intangible asset impairment charge million impairment charge bms high charge contingent tax matter offset favorable earning mix high plavix sale retroactive reinstatement rd credit legislation item financial statementsnote income taxis detail noncontrolle interest item financial statementsnote alliance discussion plavix avaproavalide partnership sanofi territory cover america decrease noncontrolle interest result exclusivity loss plavix avaproavalide march summary noncontrolle interest follow year end december dollar million sanofi partnership noncontrolle interestpretax income taxis net earning attributable noncontrolle interest bristolmyer squibb nongaap financial measure nongaap financial measure include nongaap earning relate eps information adjust exclude certain cost expense gain loss specify item significant andor unusual nature evaluate individual basis similar charge gain item recognize prior period reasonably possible reoccur future period nongaap information intend portray result baseline performance include discovery development licensing manufacturing marketing distribution sale pharmaceutical product global basis enhance investor overall understanding past financial performance prospect future example nongaap earning ep information indication baseline performance item consider reflective ongoing result addition information primary indicator use basis evaluate performance allocate resource set incentive compensation target planning forecast future period information intend consider isolation substitute net earning dilute eps prepared accordance gaap specify item follow year end december dollar millions accelerate depreciation asset impairment shutdown cost amortization acquire amylin intangible asset amortization amylin alliance proceed amortization amylin inventory adjustment cost product sell stock compensation accelerate vest amylin award additional year brand prescription drug fee process standardization implementation cost marketing sell administrative stock compensation accelerate vest amylin award upfront milestone licensing payment iprd impairment research development impairment charge bms intangible asset provision restructure gain sale product line business asset pension curtailment settlement special termination benefit acquisition alliance relate itemsa litigation chargesrecoverie loss debt redemption outlicense intangible asset impairment upfront milestone licensing receipt incomeexpense increase pretax income income tax item specify tax chargebenefitbc income taxis increase net earning include million additional year brand prescription drug fee quarter b specify tax charge relate transfer pricing matter c specify tax benefit relate capital loss deduction annual report reconciliation gaap nongaap follow year end december dollar million share datum net earning attributable bms gaap earning attributable unvested restricted share net earning attributable bms diluted eps calculation gaap net earning attributable bms gaap specify item net earning attributable bms nongaap earning attributable unvested restricted share net earning attributable bms diluted eps calculation nongaap average common share outstanding dilute diluted eps attributable bms gaap dilute eps attributable specify item dilute eps attributable bms nongaap financial position liquidity capital resource net cashdebt position follow dollar million cash cash equivalent marketable security current marketable security noncurrent total cash cash equivalent marketable security shortterm borrowing longterm debt net cashdebt position cash cash equivalent marketable security hold approximately billion december remain billion hold primarily lowtax jurisdiction attributable earning expected indefinitely reinveste offshore cash repatriation subject restriction certain jurisdiction subject withholding additional income taxis believe exist cash cash equivalent marketable security cash generate operation sufficient satisfy normal cash requirement year include dividend capital expenditure milestone payment work capital dividend billion billion dividend decision quarterly basis board director capital expenditure approximately million past year expect increase approximately billion high spending expect result expand biologic manufacturing capability facilityrelate activity example planning construct new largescale biologic manufacturing facility ireland produce multiple therapy grow biologic portfolio complete february sell astrazeneca substantially diabete business comprise alliance result billion cash flow include royalty item financial statementsnote alliance discussion redeem note entirety outstanding principal note million management periodically evaluate potential opportunity repurchase certain debt security terminate certain interest rate swap contract prior maturity commercial paper borrowing outstanding december marketable security portfolio subject change fair value result interest rate fluctuation market factor impact result operation investment policy place limit investment time maturity investment institution policy require investment enter corporate financial institution meet high credit quality standard item financial statementsnote financial instrument fair value measurement bristolmyer squibb separate billion fiveyear revolve credit facility maintain syndicate lender facility provide customary term condition financial covenant extendable anniversary date consent lender borrowing outstanding revolve credit facility december additional regulation pass future reduce result operation operate cash flow liquidity financial flexibility continue monitor potential impact economic condition certain european country relate impact prescription trend pricing discount creditworthiness customer ability collect outstanding receivable direct customer currently believe economic condition eu material impact liquidity cash flow financial flexibility exposure certain european governmentbacke entity high risk default governmentbacke entity monitor economic factor include credit rating creditdefault swap rate debttogross domestic product ratio addition entity specific factor exposure reduce factor certain receivables include receivables italy portugal spain million million million factoring receivables japan million million million factoring agreement allow recourse event uncollectibility retain interest underlie asset sell continue manage operate cash flow focus work capital item directly affect change sale volume receivables inventory account payable december december dollar million net trade receivables inventory account payable total credit rating moodys investor service longterm shortterm credit rating prime respectively longterm credit outlook negative standard poor longterm shortterm credit rating respectively longterm credit outlook stable fitch longterm shortterm credit rating f respectively revise longterm credit outlook negative stable december credit rating consider investment grade longterm rating reflect agency opinion low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm rating reflect agency opinion good extremely strong capacity timely repayment cash flow follow discussion cash flow activity dollar million cash flow provide byused operating activity invest activity financing activity annual report operating activity cash flow operating activity represent cash receipt cash disbursement activity invest activity financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item gain loss attribute invest financing activity change operate asset liability result time difference receipt payment cash transaction recognize result operation result change cash operating activity reflect time cash collection customer alliance partner payment supplier alliance partner employee pension contribution tax payment ordinary course business million decrease cash provide operating activity primarily attributable low upfront contingent alliance proceed approximately million reckitt alliance proceed million additional net work capital requirement million partially offset time cash collection payment ordinary course business include item low pension contribution restructure annual bonus payment billion decrease cash provide operating activity primarily attributable low upfront contingent alliance proceed approximately billion amylin alliance proceed billion low operating cash flow attribute plavix avaproavalide revenue reduction follow loss exclusivity approximately million investing activity cash requirement invest activity include cash business acquisition manufacturing facilityrelate capital expenditure purchase marketable security maturity great day reduce proceed business divestiture sale maturity marketable security billion decrease cash investing activity primarily attributable proceed billion allocate diabetes business divestiture partially offset high net purchase marketable security approximately billion cash acquire ipierian million billion decrease cash investing activity primarily attributable cash acquire amylin billion inhibitex billion partially offset high net proceed sale purchase maturity marketable security approximately billion financing activity cash requirement financing activity include cash pay dividend repurchase common stock repay longterm debt borrowing reduce proceed exercise stock option issuance longterm debt borrowing billion increase cash financing activity primarily attributable low net borrowing longterm debt transaction billion million repayment million net borrowing low proceed stock option exercise million million include excess tax benefit partially offset low cash repurchase common stock million billion decrease cash financing activity primarily attributable low cash repurchase common stock billion million billion high net borrowing longterm debt transaction billion million net borrowing million net repayment include debt assume amylin acquisition high proceed stock option exercise million million include excess tax benefit bristolmyer squibb contractual obligation payment period contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt interest longterm debta operating lease purchase obligation uncertain tax positionsb longterm liability total include estimate future interest payment periodic cash settlement derivative b include shortterm uncertain tax benefit uncertainty timing resolution addition commit aggregate billion potential future research development milestone payment party inlicense development program include earlystage milestone million milestone achieve phase iii clinical trial latestage milestone billion milestone achieve post phase iii clinical trial payment generally payable achievement certain developmental regulatory milestone specific timing predict agreement provide salesbased milestone aggregate billion obligate pay alliance partner achievement certain sale level addition royalty certain manufacturing development commercialization obligation connection alliance arrangement practicable estimate obligation item financial statementsnote alliance information alliance discussion contractual obligation item financial statementsnote income taxis note financial instrument fair value measurement note pension postretirement postemployment liability note lease sec consent order previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form q period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec b establish business risk disclosure group c retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand e ensure budget process give appropriate weight input come adequately document process establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis maintain inventory management agreement imas pharmaceutical wholesaler account nearly gross revenue current term ima wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product large wholesaler currently account approximately gross revenue inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast nonus business significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty annual report demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent recently issue accounting standard recently issue accounting standard item financial statementsnote accounting policiesrecently issue accounting standard critical accounting policy preparation financial statement require use estimate assumption affect report amount asset liability report amount revenue expense critical accounting policy significantly impact financial condition result operation require difficult subjective complex judgment result need estimate effect matter inherently uncertain uncertainty actual result vary estimate accounting policy discuss audit committee board director revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate revenue recognize persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally shipment certain eu market occur delivery product customer defer approximately million product sell early access program eu portion recognize revenue subject final price negotiation local government expect conclude revenue reduce grosstonet sale adjustment discuss involve significant estimate judgment consider legal interpretation applicable law regulation historical experience payer channel mix eg medicare medicaid current contract price applicable program unbilled claim processing time lag inventory level distribution channel estimate assess period adjust require revise information actual experience addition total revenue discussion analysis significant category grosstonet sale adjustment alliance arrangement involve delivery element undelivered element evaluate qualify separate unit accounting consideration fix determinable allocate undelivered element recognize related good service deliver limited consideration contingent future deliverable consideration associate contingent milestone royalty allocate underlie element amount determined payable bms grosstonet adjustment follow category grosstonet adjustment involve significant estimate judgment information obtain external source chargeback related government program business participate program government entity significant department defense department veteran affair party include cover entity b drug pricing program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account receivable reduce estimate unprocessed chargeback claim attributable sale typically week time lag cash discount certain country cash discount offer incentive prompt payment generally approximate sale price account receivable reduce estimate unprocessed cash discount typically month time lag bristolmyer squibb manage healthcare rebate contract discount rebate discount offer manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit addition commercial plan contract counterpartie hospital group purchasing organization globally rebate require department defense tricare retail pharmacy refund program estimate unpaid unbilled rebate discount present liability million reversal estimate medicare coverage gap discount occur receipt actual invoice medicaid rebate business participate state government medicaid program qualify federal state government program require discount rebate participate state local government entity discount rebate provide program include medicaid rebate accrual medicaid rebate extend drug manage medicaid plan estimate unpaid unbilled rebate present liability estimate medicaid rebate attributable prior period revenue reduce million million million sale return product typically eligible return month prior month product expiration accordance policy estimate return establish product determine consider historical experience factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product low demand follow loss exclusivity estimate product return present liability reserve establish plavix avaproavalide follow loss exclusivity remain reserve million million december respectively consider relevant factor estimate future retail wholesale inventory work occur loss exclusivity estimate return new product determine consider historical sale return experience similar product product line similar therapeutic category defer recognition revenue right return expire sufficient historical experience estimate sale return develop limited circumstance typically occur new product extension exist line product historical experience product similar therapeutic category lack estimate level inventory distribution channel project demand consider estimate sale return new product use information external source information external source estimate grosstonet adjustment estimate inventory wholesaler base project prescription demandbase sale product historical inventory experience analysis party information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information retirement benefit account pension postretirement benefit plan require actuarial valuation base significant assumption discount rate expect longterm rate return plan asset consultation actuary significant assumption salary growth retirement turnover healthcare trend mortality rate evaluate select base expectation actual experience remeasurement date pension expense vary range outcome material effect report earning project benefit obligation future cash fund actual result give year differ estimate economic factor annual report yield high quality corporate bond coincide cash flow plan estimate payout determine discount rate citigroup pension discount curve plan plan pension expense determine weightedaverage discount rate present value benefit obligation december pension plan determine discount rate discount rate determine plan pension expense reduce additional expense increase approximately million assumed discount rate determine pension plan project benefit obligation december reduce additional project benefit obligation increase approximately billion new mortality table rp mortality improvement scale mp issue society actuary reflect long life expectancie previous table new table measure pension postretirement obligation begin september result increase obligation approximately million revise mortality rate expect materially impact pension expense future period expect longterm rate return plan asset estimate consider expect return individual asset class input external advisor consider longterm historical return include actual performance compare benchmark similar investment plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million detailed discussion retirement benefit item financial statementsnote pension postretirement postemployment liabilitie business combination divestiture goodwill intangible asset acquire business combination licensing transaction billion represent total asset december accounting transaction business combination divestiture significantly different asset acquisition divestiture example acquire iprd capitalize business combination expense asset acquisition fair value contingent consideration goodwill recognize business combination transaction likewise portion report unit constitute business divest goodwill associate business include carry value business determine gain loss derecognition goodwill occur asset disposition result important determine business asset group asset acquire divest business define asc business combination integrate set input process capable generate output ability provide return investor owner typical input include longlive asset include intangible asset right use longlived asset intellectual property ability obtain access require resource typical process include strategic operational resource management process typically document evident organized workforce consider factor determine business acquire divest stage development commercial product involve example evaluate acquisition ipierian conclude significant process transfer transaction account asset acquisition result million allocate lead investigational compound expense capitalize addition contingent consideration potential regulatory approval milestone million salesbase royalty include purchase price similarly evaluate divestiture diabetes franchise astrazeneca conclude necessary input process transfer consequently transaction account sale business result allocation million goodwill carry value business determine gain sale business combination transaction asset acquire liability assume recognize date acquisition respective fair value excess purchase price estimate fair value net asset acquire recognize goodwill fair value intangible asset include iprd typically determine income method method starts forecast net cash flow risk adjust estimate probability technical regulatory success iprd adjust present value appropriate discount rate reflect risk associate cash flow stream asset value market participant view different specific bms view valuation process complex require significant input judgment internal external source valuation required finalize oneyear period consider fact evidence available acquisition date complex judgmental matter applicable valuation process summarize bristolmyers squibb unit account intangible asset value single global asset multiple asset jurisdiction indication consider development stage expect level incremental cost obtain additional approval risk associate development time benefit expect derive future expect patent live jurisdiction intention promote asset global brand estimate useful life asset life expect contribute meaningful cash flow determine consider pertinent matter associate asset include expect regulatory approval date unapproved exclusivity period legal regulatory contractual provision effect obsolescence demand competition economic factor include barrier entry probability technical regulatory success ptrs rate ptrs rate determine base industry average consider respective program development stage disease indication adjust specific information datum know acquisition date subsequent clinical result internal external datum obtain alter ptrs rate materially impact estimate fair value intangible asset subsequent period leading impairment charge projection future revenue estimate consider factor initial market opportunity pricing sale trajectory peak sale level competitive environment product evolution future cost expense estimate consider historical market trend market participant synergy timing level additional development cost obtain initial additional regulatory approval maintain enhance product generally assume initial positive cash flow commence shortly receipt expect regulatory approval typically occur number year actual cash flow attribute project likely different assume projection subject multiple factor include trial result regulatory matter materially change ultimate commercial success asset significantly alter cost develop respective asset commercially viable product tax rate expect future income tax effect market participant tax rate recent valuation typically use tax rate applicable state taxis consider jurisdiction intellectual property hold location research manufacturing infrastructure consider earning repatriation likely tax consequence discount rate discount rate select consider risk inherent future cash flow assessment asset life cycle competitive trend impact asset include consideration technical legal regulatory economic barrier entry expect change standard practice indication address asset item financial statementsnote acquisition specific detail value assign asset acquire liability assume acquisition ipierian amylin inhibitex significant estimate utilize time valuation support fair value lead compound acquisition include estimate phase year discount useful life development ptrs rate project positive dollar million fair value rate utilize year acquisition date utilize cash flow commercialize product bydureon na na na byetta na na na symlin na na na iprd bms inx na phase ii myalept na phase iii valuation process require certain multiple element arrangement include determination judgmental complex matter discuss example divestiture diabetes business astrazeneca require determination well estimate selling price element include business supply development agreement include appropriate markup estimate fair value manufacturing facility item financial statementsnote alliance discussion annual report impairment goodwill goodwill billion december goodwill test annually impairment enterprise level assess qualitative factor perform quantitative analysis determine likely fair value exceed carry value example qualitative factor assess current year include share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year positive negative influence relevant factor assess individually aggregate result conclude additional quantitative testing require discussion goodwill acquire inprocess research development intangible asset item financial statement note accounting policiesgoodwill acquire inprocess research development intangible asset intangible asset include iprd intangible asset billion december include license million develop technology right million capitalize software million iprd million intangible asset assess impairment current fact circumstance warrant review iprd assess annually intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment common potential risk leading impairment include competition early expect loss exclusivity pricing pressure adverse regulatory change clinical trial result delay failure obtain regulatory approval additional development cost inability achieve expect synergy high operating cost change tax law macroeconomic change complexity estimate fair value intangible asset connection impairment test similar initial valuation consider high risk nature research development industry success rate bring developmental compound market iprd impairment charge likely occur future period recognize charge million include million charge peginterferon lambda phase iii development treatment hcv recognize charge billion include billion charge result discontinue development bms project previously acquire medarex inc inhibitex acquisition result unfavorable clinical trial result additional development cost extend development period decision cease development iprd closely monitor assess period impairment discussion iprd impairment item financial statementsnote goodwill intangible asset addition iprd commercial asset subject impairment example impairment charge million recognize related nonkey product prior acquisition continue competitive pricing pressure operate dynamic market regulatory environment event occur cause expectation change quickly lead potential impairment charge property plant equipment property plant equipment test impairment current fact circumstance warrant review additionally longlive asset periodically review determine change fact circumstance result change estimate useful life asset possibly result acceleration depreciation circumstance exist estimate undiscounted future cash flow generate asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value expectation future cash flow subject change base near longterm production volume margin generate asset potential alternative future use accelerate depreciation relate charge certain manufacturing facility million million million contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency item financial statementsnote accounting policiescontingencie note income taxis note legal proceeding contingency bristolmyer squibb income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment defer tax asset billion december net valuation allowance billion billion december net valuation allowance billion defer tax asset relate federal net operating loss carryforward million federal tax credit carryforward million recognize december net operating loss carryforward expire vary amount begin federal tax credit carryforward expire vary amount begin realization carryforward dependent generating sufficient domesticsource taxable income prior expiration assured believe likely defer tax asset realize addition defer tax asset relate federal state capital loss million recognize december carry year carry forward year realization carryforward dependent generate sufficient capital gain prior expiration million valuation allowance establish item december taxis provide undistributed earning foreign subsidiary expect reinveste indefinitely offshore prior mead johnson nutrition company mead johnson splitoff follow transaction occur internal spin mead johnson share own ii conversion mead johnson class b share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class b share class share outside legal opinion certain assumption representation covenant mead johnson rely future conduct business matter affect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction transaction subject tax exchange taxable sale market value addition negative basis excess loss account ela exist investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code irs assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation agree certain tax relate indemnity mead johnson set forth tax sharing agreement include certain taxis relate business prior completion ipo create restructure facilitate ipo mead johnson agreed indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know example additional reserve million establish certain transfer pricing matter relate period discussion income taxis item financial statementsnote accounting policiesincome taxis note income taxis annual report special note forwardlooke statement annual report include document incorporate reference write oral statement time time contain certain forwardlooking statement meaning section security act section e securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year include important factor cautionary statement include annual report particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date undertake obligation release publicly revision forwardlooke statement result new information future event bristolmyer squibb quantitative qualitative disclosure market risk expose market risk result change currency exchange rate interest rate certain derivative financial instrument available costeffective basis hedge underlie economic exposure financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant amount revenue earning cash flow expose change foreign currency rate primary net foreign currency translation exposure euro japanese yen chinese renminbi canadian dollar south korean foreign currency forward contract manage risk primarily arise certain intercompany purchase transaction designate foreign currency cash flow hedge appropriate addition expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate nonus dollar currency foreign currency forward contract offset exposure designate hedge estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract million december reduce earning remain life contract expose translation risk nonus dollardenominate net asset nonus dollar borrowing hedge foreign currency exposure net investment certain foreign affiliate designate hedge net investment effective portion foreign exchange gain loss hedge include foreign currency translation component accumulate comprehensive incomeloss net investment decrease equivalent value nonus debt borrowing change remeasurement basis debt subject recognition income change occur additional information item financial statementsnote financial instrument fair value measurement interest rate risk fixedtofloate interest rate swap contract designate fairvalue hedge interest rate risk management strategy contract intend provide appropriate balance fix float rate debt estimate increase basis point shortterm longterm interest rate decrease fair value interest rate swap contract million exclude effect counterparty credit risk reduce earning remain life contract estimate increase basis point longterm interest rate decrease fair value longterm debt million marketable security subject change fair value result interest rate fluctuation market factor policy inv institution meet high credit quality standard estimate increase basis point interest rate general decrease fair value debt security portfolio approximately million credit risk material certain european governmentbacke entity high risk default monitor economic factor include credit rating creditdefault swap rate debttogross domestic product ratio entity specific factor historically exposure limited factoring receivables credit exposure europe increase future reduction factor arrangement ongoe sovereign debt crisis credit exposure trade receivables greece portugal italy spain approximately million december approximately governmentbacke entity monitor investment counterpartie objective minimize concentration credit risk investment policy establishe limit time maturity investment individual counterparty policy require investment enter corporate financial institution meet high credit quality standard use derivative instrument expose credit risk fair value derivative instrument contract positive expose credit risk counterparty fails perform fair value derivative instrument contract negative counterparty expose credit risk fail perform obligation collateral require party derivative asset liability position policy diversify derivative counterpartie mitigate overall risk counterparty default additional information item financial statementsnote financial instrument fair value measurement annual report consolidate statement earning dollar share million share datum year end december earning net product sale alliance revenue total revenue cost product sell marketing sell administrative advertising product promotion research development impairment charge bms intangible asset incomeexpense total expense earning income taxis provision forbenefit income taxis net earning net earning attributable noncontrolle interest net earning attributable bms earning common share basic diluted cash dividend declare common share consolidate statement comprehensive income dollar millions year end december comprehensive income net earning comprehensive incomeloss net taxis reclassification earning derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation total comprehensive incomeloss comprehensive income comprehensive income attributable noncontrolle interest comprehensive income attributable bms accompany note integral consolidated financial statement bristolmyers squibb consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable security receivables inventory defer income taxis prepaid expense asset heldforsale total current asset property plant equipment goodwill intangible asset defer income taxis marketable security asset total asset liability current liability shortterm borrowing account payable accrue expense defer income accrue rebate return income taxis payable dividend payable liability related asset heldforsale total current liability pension postretirement postemployment liability defer income income taxis payable liability longterm debt total liability commitment contingency note equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement annual report consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity net earning attributable noncontrolle interest depreciation amortization net defer income taxis stockbase compensation impairment charge pension settlement amortization proceed amylin diabetes alliance gain sale business change operate asset liability receivable inventory account payable deferred income income taxis payable net cash provide operating activity cash flow invest activity proceed sale maturity marketable security purchase marketable security addition property plant equipment capitalize software business divestiture proceed business acquisition payment net cash provide byused investing activity cash flow financing activity shortterm debt borrowing net proceed issuance longterm debt repayment longterm debt interest rate swap contract termination issuance common stock repurchase common stock dividend net cash financing activity effect exchange rate cash cash equivalent increasedecrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement bristolmyers squibb note accounting policy basis consolidation consolidate financial statement prepare conformity united states generally accept accounting principle gaap include account bristolmyer squibb company control majorityowned subsidiary certain variable interest entity refer bristolmyer squibb bms company intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date alliance license arrangement assess determine term provide economic control entity require consolidation entity entity control mean majority voting interest refer variable interest entity consolidate bms power direct activity variable interest entity significantly impact economic performance obligation absorb loss right receive benefit potentially significant entity use estimate preparation financial statement require use management estimate assumption significant assumption estimate determine fair value potential impairment intangible asset sale rebate return accrual legal contingency income taxis estimate selling price multiple element arrangement pension postretirement benefit actual result differ estimate result reclassification certain prior period amount reclassify conform current period presentation revenue recognition revenue recognize persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally time shipment include supply commercial product alliance partner principal end customer sale certain revenue nonus business recognize date receipt customer alliance revenue relate abilify atripla recognize product sell end customer alliance partner royalty base thirdparty sale recognize earn accordance contract term thirdparty sale reliably measurable collectability reasonably assure refer note alliance detail alliance provision time revenue recognition expect sale return discount rebate estimate sale allowance base historical experience update change fact circumstance include impact applicable healthcare legislation provision recognize reduction revenuewhen new product extension exist line product historical experience product similar therapeutic category revenue defer right return long exist sufficient historical experience estimate sale return develop income taxis provision income taxis include income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment tax benefit recognize uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize financial statement particular tax position base large benefit likely realize settlement annual report cash cash equivalent cash cash equivalent include treasury security government agency security bank deposit time deposit money market fund cash equivalent consist highly liquid investment original maturity month time purchase recognize cost approximate fair value marketable security investment company marketable security classify availableforsale date purchase report fair value fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity investment own company account equity method accounting ability exercise significant influence maintain share net income loss equity investment include equity net income affiliate incomeexpense equity investment review impairment assess decline market value investment carry value temporary consider intent ability retain investment length time extent market value cost financial condition investee inventory valuation inventory state low average cost market property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation compute straightline method base estimate useful life relate asset range year building year machinery equipment fixture impairment longlive asset current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique level fair value input include discount value estimate future cash flow capitalize software eligible cost obtain internal use software significant system project capitalize amortize estimate useful life software insignificant cost obtain software project expense incur business combination business acquire consolidate obtain control acquiree fair value asset acquire liability assume recognize date acquisition excess purchase price estimate fair value net asset acquire recognize goodwill legal audit business valuation business acquisition cost expense incur goodwill acquire inprocess research development intangible asset fair value intangible asset typically determine income method utilize level fair value input market participant valuation assume global view consider potential jurisdiction indication base discount aftertax cash flow projection risk adjust estimate probability technical regulatory success iprd finitelive intangible asset include license develop technology right iprd project reach commercialization amortize straightline basis estimate useful life estimate useful life determine consider period asset expect contribute future cash flow bristolmyer squibb goodwill tested annually impairment assess qualitative factor perform quantitative analysis determine likely fair value net asset carry amount example qualitative factor assess include share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year relevant factor assess individually aggregate iprd test impairment annual basis frequently event occur circumstance change indicate potential reduction fair value asset carry value carry value iprd determine exceed fair value impairment loss recognize difference finitelive intangible asset test impairment fact circumstance suggest carry value asset recoverable carrying value exceed project undiscounted pretax cash flow intangible asset impairment loss equal excess carrying value estimate fair value discount aftertax cash flow recognize restructure restructuring charge recognize result action streamline operation rationalize manufacture facility estimate impact restructuring plan include future termination benefit exit cost require judgment actual result vary estimate contingency loss contingency legal proceeding claim occur wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency include contingent proceed related divestiture recognize realize legal fee expense incur derivative financial instrument derivative principally management interest rate foreign currency exposure hold trading purpose derivative recognize fair value change fair value recognize earning specific hedge criterion meet derivative designate fair value hedge change fair value derivative hedge item attributable hedge risk recognize earning derivative designate cash flow hedge effective portion change fair value derivative report accumulate comprehensive incomeloss oci subsequently recognize earning hedge item affect earning cash flow classify consistent underlying hedged item derivative designate assign hedge forecast transaction specific asset specific liability hedge asset liability sell extinguish forecast transaction hedge long probable occur gain loss immediately recognize earning nonderivative instrument primarily euro denominate longterm debt designate hedge net investment foreign affiliate effective portion designate nonderivative instrument recognize foreign currency translation section oci ineffective portion recognize earning shipping handle cost shipping handling cost include marketing sell administrative expense million million million advertising product promotion cost advertising product promotion cost expense incur foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize oci annual report research development research development cost expense incur clinical study cost accrue service period specify contract adjust necessary base ongoing review level effort cost actually incur strategic alliance party provide right develop manufacture market andor sell pharmaceutical product right own party research development recognize net reimbursement connection alliance agreement recently issue accounting standard april financial accounting standard board fasb issue amend guidance use presentation discontinue operation entity consolidated financial statement new guidance restrict presentation discontinue operation business circumstance disposal business operation represent strategic shift major effect entity operation financial result guidance effective january adoption prospective basis fasb issue new standard relate revenue recognition require entity recognize revenue expect entitle transfer promise good service customer new standard replace exist revenue recognition standard gaap effective january early adoption permit new standard apply retrospectively prior reporting period present retrospectively cumulative effect change recognize date initial application retain earning company assess potential impact new standard financial reporting select transition method note business segment information bms operate single segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization supply chain organization responsible development delivery product market regional commercial organization distribute sell product business support global corporate staff function segment information consistent financial information regularly review chief executive officer purpose evaluate performance allocate resource set incentive compensation target planning forecast future period product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross revenue large pharmaceutical wholesaler percentage global gross revenue follow mckesson corporation cardinal health inc amerisourcebergen corporation select geographic area information follow total revenue property plant equipment dollar millions united states europe rest world othera total total revenue include royalty alliancerelate revenue product sell regional commercial organization bristolmyers squibb total revenue key product follow year end december dollar million virology baraclude entecavir hepatitis c franchisea reyataz atazanavir sulfate sustiva efavirenz franchiseb oncology erbitux cetuximab opdivo nivolumab sprycel dasatinib yervoy ipilimumab neuroscience abilify aripiprazolec immunoscience orencia abatacept cardiovascular eliquis apixaban diabetes alliance mature product othere total revenue include daklinza daclatasvir revenue million sunvepra asunaprevir revenue million b include alliance revenues million million million c include alliance revenues million million million include bydureon exenatide extendedrelease injectable suspension byetta exenatide farxigaxigduo dapagliflozindapagliflozin metformin hydrochloride onglyzakombiglyze saxagliptinsaxagliptin metformin myalept metreleptin symlin pramlintide acetate bms sell diabetes business astrazeneca february e include plavix clopidogrel bisulfate revenues million million million additionally include avaproavalide irbesartanirbesartanhydrochlorothiazide revenue million million million note alliance bms enter collaboration arrangement party development commercialization certain product arrangement unique nature party active participant operating activity collaboration expose significant risk reward depend commercial success activity bms inlicense intellectual property own party outlicense intellectual property party arrangement typically include research development manufacturing andor commercial activity cover single investigational compound commercial product multiple compound andor product life cycle stage refer collaboration alliance partner alliance partner key product abilify sprycel sustiva atripla eliquis erbitux opdivo product comprise diabetes alliance discuss certain mature brand include alliance arrangement payment alliance partner account present result operation consider specific nature payment underlie activity payment relate multiple alliance activity include transfer right separate individual unit account standalone value activity occur life arrangement situation arrangement consideration allocate activity right relative sell price basis multiple alliance activity right standalone value combine single unit account common activity bms alliance partner present result operation follow bms principal end customer sale product sale include net product sale bms alliance partner principal end customer sale bms contractual share thirdparty sale andor royalty income include alliance revenue sale commercial product consider bms ongoing major central operation refer revenue recognition include note accounting policy information recognition criterion amount payable bms alliance partner principal end customer sale supply commercial product include alliance revenue sale commercial product consider bms ongoing major central operation annual report amount payable bms alliance partner profit sharing royalty salesbase fee include cost product sell incur cost reimbursement party recognize incur include cost product sell marketing sell administrative expense advertising product promotion expense research development expense base underlying nature relate activity subject reimbursement upfront contingent development approval milestone payable bms alliance partner investigational compound commercial product defer amortize short contractual term period relate compound product expect contribute future cash flow amortization present consistent nature payment arrangement example amount receive investigational compound present incomeexpense activity perform time relate sale commercial product bmss ongoing major central operation amount receive commercial product present alliance revenue sale commercial product consider bmss ongoing major central operation astrazeneca plc astrazeneca alliance pertain amylin product discussion specific astrazeneca alliance disclosure upfront contingent approval milestone payable bms alliance partner commercial product capitalize amortize short contractual term period relate product expect contribute future cash flow amortization include cost product sell upfront contingent milestone payable bms alliance partner prior regulatory approval expense incur include research development expense equity net income affiliate include incomeexpense payment bms alliance partner present cash flow operating activity describe select financial information pertain alliance follow include net product sale bms principal thirdparty customer sale product subject alliance expense summarize include amount attribute activity product alliance payment alliance partner relate amortization payment defer capitalize year end december dollar millions revenue alliance net product sale alliance revenue total revenue payment tofrom alliance partner cost product sell marketing sell administrative advertising product promotion research development incomeexpense noncontrolle interest pretax select alliance balance sheet information december dollar million receivable alliance partner account payable alliance partner defer income alliancesa include defer income classify liability related asset heldforsale million december specific information pertain significant alliance discuss include nature purpose significant right obligation party specific accounting policy election income statement classification amount attributable payment party bristolmyer squibb otsuka bms worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote abilify exclude certain asian country portion agreement amend expire expect loss product exclusivity april agreement expire european union eu countries june nonus country exclusive right sell abilify agreement expire later april loss exclusivity country party actively participate joint executive governance operate committee otsuka assume responsibility provide funding sale force effort effective january amendment bms responsible funding certain operating expense annual limit bms purchase active pharmaceutical ingredient api otsuka complete manufacture product subsequent sale thirdparty customer certain country otsuka assume responsibility provide funding sale force effort eu effective april bms provide certain service include distribution customer management pharmacovigilence otsuka principal thirdparty product sale principal eu prior termination june bms principal thirdparty product sale exclusive distributor exclusive right sell abilify alliance revenue recognize bmss share total net sale thirdparty customer territorie bmss contractual share begin january bmss contractual share change percentage total net sale set forth table assessment bms expect annual contractual share complete quarterly reporting period adjust base report abilify net sale year end bms annual contractual share alliance revenue recognize interim period quarter exceed amount contract annual net sale bms share net sale billion billion billion billion billion billion billion billion billion excess billion eu bmss contractual share thirdparty net sale country alliance revenue recognize abilify ship risk reward ownership transfer thirdparty customer term amendment bm pay otsuka million amortize reduction alliance revenue expect loss exclusivity april unamortized balance include asset otsuka receive royalty base total net sale include cost product sell otsuka responsible expense relate commercialization abilify bms otsuka alliance sprycel ixempra ixabepilone japan eu party actively participate governance committee bms control decision make party copromote product bms responsible development manufacture product principal endcustomer product sale fee pay otsuka base follow percentage annual net sale sprycel ixempra net sale million million million million million million billion excess billion annual period otsuka contribute million certain commercial operational expense relate oncology product oncology territory cost excess million annual report summarize financial information relate alliance follow year end december dollar million revenue otsuka alliance net product sale alliance revenuesa total revenue payment tofrom otsuka cost product sell oncology fee royalty amortization intangible asset cost product supply cost reimbursement tofrom otsuka recognize cost product sell marketing sell administrative advertising product promotion research development incomeexpense select alliance balance sheet information december dollar million asset extension payment include amortization extension payment reduction alliance revenue million astrazeneca prior diabetes business divestiture discuss bms alliance astrazeneca consist worldwide co development commercialization agreement cover onglyza relate combination product sell name farxiga relate combination product begin august bms acquisition amylin pharmaceuticals inc amylin amylin portfolio product include bydureon byetta symlin myalept certain asset own amylin include manufacturing facility locate west chester ohio coexclusive license right product product underlying agreement grant astrazeneca exchange upfront payment potential milestone payment party assume certain obligation actively participate alliance party actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms manufacture product alliance principal endcustomer product sale substantially country alliance agreement right transfer astrazeneca standalone value right sell separately bms party astrazeneca receive benefit deliver right fulfillment ongoing obligation bms alliance agreement include exclusive supply arrangement global alliance treat single unit accounting result upfront proceed subsequent contingent milestone proceed amortize life relate product bms receive billion nonrefundable upfront payment astrazeneca consideration enter amylin alliance astrazeneca exercise option equal governance right certain key strategic financial decision amylin alliance pay bms million consideration payment account deferred income amortize base relative fair value predominant element include alliance estimate useful life intangible asset relate bydureon estimate useful life year byetta estimate useful life year symlin estimate life year myalept estimate useful life year amylin manufacture plant estimate useful life year amortization present reduction cost product sell alliance asset acquire shortly commencement alliance astrazeneca entitle share proceed sale asset amortization bristolmyers squibb acquire amylin intangible asset manufacturing plant present cost product sell bms entitle reimbursement capital expenditure relate acquire amylin manufacturing facility bms astrazeneca share certain tax attribute relate amylin alliance prior termination alliance bms receive nonrefundable upfront milestone licensing payment million relate onglyza million relate farxiga amortization onglyza farxiga deferred income include income onglyza farxiga commercial product commencement alliance party share commercialization development expense equally profit loss february bms astrazeneca terminate alliance agreement bms sell astrazeneca substantially diabete business comprise alliance divestiture include share amylin result transfer ohio manufacturing facility intellectual property relate onglyza farxiga include bms interest outlicensing agreement onglyza japan future purchase bmss manufacturing facility locate mount vernon indiana substantially employee dedicated diabetes business transfer astrazeneca sale business complete jurisdiction bms astrazeneca enter agreement connection sale include supply agreement development agreement transitional service agreement agreement bms obligate supply certain product include active product ingredient onglyza farxiga perform ongoing development activity certain clinical trial program provide transitional service account financial service customer service distribution regulatory development information technology certain administrative service period order facilitate orderly transfer business operation annual cost attribute development agreement expect exceed approximately million consideration transaction include billion payment close contingent regulatory salesbase milestone payment billion include million relate approval milestone million relate salesbased milestone payable royalty payment base net sale payment million certain asset transfer astrazeneca astrazeneca pay bms require product supply price approximating product cost negotiate transitional service fee royalty rate net sale follow onglyza farxiga worldwide net sale million onglyza farxiga worldwide net sale million amylin product net sale stock asset purchase agreement contain multiple element deliver subsequent closing transaction include china diabete business transfer quarter mount vernon indiana manufacturing facility activity development supply agreement element determine standalone value result portion consideration receive closing allocate undelivered element relative selling price method determine well estimate selling price element remain consideration include calculation gain sale diabete business contingent milestone royalty payment similarly allocate underlie element amount determined payable bms amount allocate sale business immediately recognize result operation amount allocate element recognize result operation extent element deliver consideration billion account substantially quarter include royalty million contingent regulatory milestone payment relate approval farxiga japan approximately billion consideration allocate sale business remain million allocate undelivered element describe consideration include million earn royalty include million allocate element deliver gain sale diabete business million include million quarter result primarily transfer china diabete business astrazeneca gain base difference consideration allocate sale business exclude royalty net transaction fee carry value diabete business net asset include million allocation goodwill reversal million net defer tax liability attribute amylin annual report consideration allocate mount vernon indiana manufacturing facility continue defer transfer astrazeneca consideration allocate development supply agreement continue amortize applicable service period amortization defer income attribute development agreement include income sale service consider bmss ongoing major central operation revenue attribute supply agreement include alliance revenue consideration transaction present cash flow purpose base allocation process describe invest activity attribute sale business relate asset operating activity attribute transitional service supply arrangement development agreement summarize financial information relate astrazeneca alliance follow year end december dollar millions revenue astrazeneca alliance net product sale alliance revenue total revenue payment tofrom astrazeneca cost product sell profit sharing amortization defer income cost reimbursement tofrom astrazeneca recognize cost product sell marketing sell administrative advertising product promotion research development incomeexpense amortization defer income provision restructure royalty transitional service gain sale business select alliance cash flow information defer income business divestiture proceed select alliance balance sheet information december dollar millions deferred income attribute nonrefundable upfront milestone licensing receiptsa asset transfer astrazeneca service perform astrazeneca include liability relate asset heldforsale december bristolmyers squibb gilead bms gilead sciences inc gilead joint venture canada europe develop commercialize atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg combine sustiva product bms truvada emtricitabine tenofovir disoproxil fumarate product gilead joint venture consolidate gilead party actively participate joint executive committee operating committee direct oversight activity joint venture joint venture purchase sustiva truvada api bulk form party complete finishing atripla joint venture gilead sell distribute atripla principal thirdparty customer sale party long coordinate joint promotional activity alliance revenue recognize atripla include bulk efavirenz component atripla base relative ratio average respective net selling price truvada sustiva alliance revenue defer related alliance receivable recognize combined product sell thirdparty customer europe follow loss exclusivity sustiva effective january percentage atripla net sale europe recognize bms equal difference average net selling price atripla truvada alliance continue europe party terminate arrangement patent expiration occur atripla truvada sustiva agreement terminate gilead launch generic version sustiva bms launch generic version truvada event gilead terminate agreement loss exclusivity sustiva bms receive quarterly royalty payment month follow termination payment month follow termination equal atripla net sale multiply ratio difference average net selling price atripla truvada atripla average net selling price second year follow termination payment bms reduce respectively atripla net sale multiply price ratio describe bms continue supply sustiva cost plus markup joint venture threeyear period party elect terminate supply arrangement summarize financial information relate alliance follow year end december dollar million revenue gilead alliance alliance revenues equity net loss affiliate select alliance balance sheet information december dollar millions defer income lilly bms epidermal growth factor receptor egfr commercialization agreement eli lilly company lilly lilly subsidiary imclone codevelopment copromotion erbitux canada japan egfr agreement party actively participate joint executive committee operating committee share responsibility research development resource infrastructure respect erbitux lilly manufacture bulk requirement cetuximab facility fill finish perform party bms oversight responsibility bms responsible promotional effort north america lilly right copromote expense bms codevelopment copromotion right canada japan bms principal thirdparty customer sale north america pay lilly distribution fee erbitux net sale north america plus share certain royalty pay lilly agreement expire erbitux north america september bms share right erbitux japan agreement lilly merck kgaa receive pretax profit merck kgaas net sale erbitux japan share equally lilly december bms agree transfer cocommercialization right japan merck kgaa exchange future royalty include income earn annual report march bms lilly terminate arrangement necitumumab imcf right return lilly discover imclone necitumumab fully human monoclonal antibody alliance bms lilly license acquisition cost million associate erbitux alliance agreement amortize summarize financial information relate alliance follow year end december dollar millions revenue lilly alliance net product sale alliance revenue total revenue payment tofrom lilly cost product sell distribution fee royalty amortization intangible asset cost product supply cost reimbursement tofrom lilly incomeexpense japan commercialization fee select alliance balance sheet information december dollar million intangible asset nonrefundable upfront milestone licensing payment bms acquire amylin pharmaceuticals inc amylin august note acquisition information amylin previously enter settlement termination agreement lilly alliance global development commercialization byetta bydureon exenatide product party agree transition responsibility product amylin transition operation complete prior acquisition transition nonus operation majority market complete april terminate lilly nonus exclusive right promissory note assume acquisition amylin aggregate billion repay lilly sanofi september bms sanofi restructure term codevelopment cocommercialization agreement plavix avaproavalide effective january sanofi assume essentially worldwide operation alliance exception plavix puerto rico alliance plavix market continue unchanged december term original alliance arrangement describe exchange right transfer sanofi bms receive quarterly royalty january december terminal payment sanofi million end begin royalty receive sanofi territory cover americas australia optout market development royalty present alliance revenues million million development optout royalty income million include incomeexpense development royalty expense sanofi million present cost product sell million present incomeexpense royalty attribute territory cover europe asia continue earn territory partnership include equity net income affiliate equity net income affiliate include million profit defer prior restructure agreement alliance revenue attribute supply irbesartan api sanofi million million million supply arrangement irbesartan expire prior restructure bmss worldwide alliance sanofi codevelopment cocommercialization avaproavalide plavix operate framework geographic territory america principally canada puerto rico latin american countries australia europe asia territory partnership manage central expense market research development royalty supply finish product individual country bms act operating partner own majority control interest territory cover americas australia consolidated country partnership result territory sanofis share result reflect noncontrolle interest bms recognize net product sale comarkete country outside territory eg italy irbesartan germany greece spain bristolmyers squibb sanofi act operating partner own majority control interest territory cover europe asia bms ownership interest territory summarize financial information relate alliance follow year end december dollar millions revenue sanofi alliance net product sale alliance revenue total revenue payment tofrom sanofi cost product supply cost product sell royalty equity net income affiliate incomeexpense noncontrolle interest pretax select alliance cash flow information distribution tofrom sanofi noncontrolle interest distribution sanofi investment affiliate select alliance balance sheet information december dollar million investment affiliate territory cover europe asiaa noncontrolle interest include alliance receivables follow summarize financial information interest partnership sanofi territory cover europe asia consolidated account equity method year end december dollar million net sale gross profit net income cost product sell territory cover europe asia include discovery royalty million million million pay directly sanofi expense share base applicable ownership percentage current asset current liability include approximately million million million relate receivablespayable attribute cash distribution bms sanofi intercompany balance partnership territory pfizer bms pfizer inc pfizer maintain worldwide codevelopment cocommercialization agreement eliquis anticoagulant discover bms pfizer fund development cost depend study company share profit loss equally global basis certain country pfizer commercialize eliquis pay bms compensation base percentage net sale enter agreement coexclusive license right product grant pfizer exchange upfront payment potential milestone payment party assume certain obligation actively participate alliance actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms manufacture product alliance principal endcustomer product sale country annual report determine right transfer pfizer standalone value right sell separately bms party pfizer receive benefit deliver right fulfillment ongoing obligation bms alliance agreement include exclusive supply arrangement global alliance treat single unit accounting upfront proceed subsequent contingent milestone proceed amortize life relate product bms receive million nonrefundable upfront milestone licensing payment relate eliquis date amortization eliquis defer income include income eliquis commercial product commencement alliance summarize financial information relate alliance follow year end december dollar millions revenue pfizer alliance net product sale alliance revenue total revenue payment tofrom pfizer cost product sell profit sharing cost reimbursement tofrom pfizer incomeexpense amortization defer income select alliance cash flow information defer income select alliance balance sheet information december dollar millions defer income reckitt benckiser group bms reckitt benckiser group plc reckitt enter threeyear alliance overthecounterproduct sell primarily mexico brazil net sale product approximately million reckitt receive right sell distribute market product certain responsibility relate regulatory matter cover territory bms receive royalty net sale product exclusively supply certain product reckitt cost plus markup certain limited asset include market authorization certain employee directly attribute business transfer reckitt start alliance period bms retain ownership asset relate business include trademark cover product bms grant reckitt option acquire trademark inventory certain asset exclusively relate product end alliance period price determine base multiple sale plus cost remain inventory hold bms time april alliance modify provide option reckitt purchase bms manufacturing facility locate mexico primarily dedicated product include alliance option exercise substantially employee facility expect transfer reckitt option exercise option exercise asset previously transfer reckitt revert bms option exercise reckitt november case closing expect occur nonrefundable upfront proceed million receive bms allocate unit account include right transfer reckitt fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option determine level input include liability million charge include expense increase fair value option million allocate right transfer reckitt amortize alliance revenue contractual term bristolmyer squibb summarize financial information relate alliance follow year end december dollar millions revenues reckitt alliance alliance revenues select alliance cash flow information defer income change operate asset liability select alliance balance sheet information december dollar millions defer income medicine company february bms medicine company enter twoyear alliance recothrom recombinant thrombin use topical hemostat control nonarterial bleed surgical procedure previously acquire bms connection acquisition zymogenetics inc net product sale recothrom million medicine company receive right sell distribute market recothrom global basis year certain responsibility relate regulatory matter cover territory bm exclusively supply recothrom medicine company cost plus markup receive royalty net sale recothrom certain employee directly attribute business certain asset transfer medicine company start alliance period include biologic license application relate regulatory asset bms retain asset relate recothrom include patent trademark inventory bms grant medicine company option acquire patent trademark inventory certain asset exclusively relate recothrom price determine base multiple sale plus cost remain inventory hold bms time medicine company exercise option acquire business million february note asset heldforsale information nonrefundable upfront proceed million receive bms allocate unit account include right transfer medicine company fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option million december determine level input include accrue expense allocate right transfer medicine company amortize alliance revenue contractual term summarize financial information relate alliance follow year end december dollar millions revenue medicines company alliance alliance revenues select alliance cash flow information defer income change operate asset liability select alliance balance sheet information december dollar millions defer income annual report valeant october bms pharmaswis sa whollyowne subsidiary valeant pharmaceuticals international inc valeant enter alliance certain mature brand product europe valeant receive right sell distribute market product europe december certain responsibility relate regulatory matter cover territory bm exclusively supply product valeant cost plus markup bms grant valeant option acquire trademark intellectual property exclusively relate product price determine base multiple sale valeant exercise option acquire business million january nonrefundable upfront proceed million receive bms allocate unit account include right transfer valeant fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option determine level input include accrue expense million charge include expense increase fair value option million allocate right transfer valeant amortize alliance revenue contractual term summarize financial information relate alliance follow year end december dollar millions revenue valeant alliance net product sale alliance revenue total revenue select alliance cash flow information defer income change operate asset liability select alliance balance sheet information december dollar millions defer income ono bms ono pharmaceutical co ltd ono alliance agreement develop commercialize opdivo antipd human monoclonal antibody investigate anticancer treatment bms exclusive right develop manufacture commercialize opdivo territory worldwide japan south korea taiwan ono responsible development commercialization prior amendment discuss ono entitle receive royalty follow regulatory approval territory exclude country list royalty rate north america applicable territory alliance agreement amend july provide additional collaboration activity japan south korea taiwan pertain opdivo bms compound include ipilimumab lirilumab urelumab bms antilag party right obligation jointly develop commercialize compound bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono codevelop cocommercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote party assign customer account bms responsible product supply copromotion fee pay party sale partys assign customer bristolmyer squibb summarize financial information relate alliance follow year end december dollar millions revenue ono alliance net product sale alliance revenue total revenue payment tofrom ono cost product sell copromotion fee cost reimbursement tofrom ono recognize research development fstar october bms enter agreement fstar alpha ltd fstar agreement provide bms exclusive option purchase fstar alpha ltd phase ready lead asset fs target therapy development treatment breast gastric cancer welldefine population herpositive patient bms pay million fstar shareholder option fee certain licensing right include research development expense responsible conducting funding development fs option exercisable bms discretion expire early day follow obtain proof concept june additional million payable exercise option plus additional aggregate consideration million contingent development regulatory approval milestone payment europe bms obligate provide additional financial support f star fstar determine business define asc business combination result contingent consideration include purchase price goodwill recognize fstar variable interest entity equity holder lack characteristic control financial interest bms determine primary beneficiary power direct activity significantly directly impact economic performance entity option right describe consolidation noncontrolle interest credit million reflect fair value fs iprd asset million defer tax liability note acquisition ipierian inc acquisition april bms acquire outstanding share ipierian inc ipierian biotechnology company focus new treatment tauopathie class neurodegenerative disease acquisition provide bms right ipn preclinical monoclonal antibody treat progressive supranuclear palsy tauopathie consideration include upfront payment million contingent development regulatory milestone payment million future royalty net sale acquire preclinical asset approve commercialize significant ipierian process acquire transaction account asset acquisition ipierian determine business upfront payment allocate ipn million include research development expense remain million allocate defer tax asset net operating loss tax credit carryforward amylin pharmaceuticals inc acquisition august bms acquire outstanding share amylin biopharmaceutical company focus discovery development commercialization innovative medicine treat diabete metabolic disease acquisition cost million include expense bms obtain commercialization right amylin primary commercialize asset bydureon onceweekly diabete treatment byetta daily diabete treatment glucagonlike peptide glp receptor agonist approve certain country improve glycemic control adult type diabete bms obtain commercialization right symlin amylinomimetic approve adjunctive therapy mealtime insulin treat diabete goodwill generate acquisition primarily attribute expansion diabetes franchise annual report iprd attribute metreleptin analog human hormone leptin study develop treatment diabetes andor hypertriglyceridemia pediatric adult patient inherit acquire lipodystrophy estimate useful life cash flow utilize value metreleptin assume initial positive cash flow commence shortly expect receipt regulatory approval subject trial result note alliancesastrazeneca discussion sale company diabetes business include amylin astrazeneca comprise global diabetes alliance inhibitex inc acquisition february bms acquire outstanding share inhibitex inc inhibitex clinicalstage biopharmaceutical company focus develop product prevent treat infectious disease acquisition cost million include expense bms obtain inhibitexs lead asset inx oral nucleotide polymerase nsb inhibitor phase ii development treatment chronic hepatitis c virus infection goodwill generate acquisition primarily attribute potential offer portfolio therapy choice hepatitis virus infection provide additional level sustainability bmss virology pipeline iprd primarily attribute inx inx expect effective combination therapy assume market participant inherently maintain franchise synergy attribute maximize cash flow exist virology pipeline asset cash flow utilize value inx include synergy assume initial positive cash flow commence shortly expect receipt regulatory approval subject trial result august company discontinue development inx interest patient safety result company recognize noncash pretax impairment charge billion information discussion impairment charge note goodwill intangible asset total consideration transfer allocation acquisition date fair value asset acquire liability assume amylin inhibitex acquisition follow dollar million identifiable net asset amylin inhibitex cash marketable security inventory property plant equipment develop technology right iprd asset debt obligation liability defer income taxis total identifiable net asset goodwill total consideration transfer cash pay acquisition amylin include payment billion outstanding common stockholder million holder stock option restrict stock unit include million attribute accelerate vest account stock compensation expense result operation cash flow acquire company include consolidated financial statement acquisition date pro forma supplemental financial information provide impact acquisition material operating result year acquisition goodwill iprd intangible asset value acquisition nondeductible tax purpose bristolmyer squibb note asset heldforsale discuss note alliance bms sell diabetes business astrazeneca february previously comprise global alliance diabete business treat single disposal group heldforsale december write require fair value business cost sell exceed related carrying value asset heldforsale december relate alliance medicine company valeant allocation goodwill base relative fair value business divest company reporting unit follow table provide asset liability classify heldforsale december december dollar million asset receivables inventory defer income taxis current prepay expense property plant equipment goodwill intangible asset asset asset heldforsale liability shortterm borrowing current portion longterm debt account payable accrue expense defer income current accrue rebate return defer income noncurrent defer income taxis noncurrent liability liabilitie relate asset heldforsale note incomeexpense incomeexpense include year end december dollar million interest expense investment income provision restructure litigation chargesrecoverie equity net income affiliate outlicense intangible asset impairment gain sale product line business asset alliance licensing income pension curtailment settlement special termination benefit incomeexpense annual report note restructuring follow provision restructuring year end december dollar million employee termination benefit exit cost provision restructure restructuring charge include employee termination benefit manufacturing sell administrative research development workforce reduction geographic region approximately restructure action primarily relate specialty care transformation initiative design create simplify organization function geographic market sale force reduction european country follow restructure sanofi otsuka alliance agreement subject local regulation cost recognize completion discussion work council additional cost million expect incur specialty care transformation initiative follow table represent activity employee termination exit cost liability year end december dollar million liability january charge change estimate provision restructure foreign currency translation amylin acquisition liability relate asset heldforsale spending liability december note income taxis provisionbenefit income taxis consist year end december dollar millions current nonus total current defer nonus total defer total provisionbenefit bristolmyer squibb effective tax rate reconciliation effective taxbenefit rate statutory federal income tax rate earning income taxis dollar million earningsloss income taxis nonus total statutory rate foreign tax effect certain operation ireland puerto rico switzerland tax effect capital loss federal state foreign contingent tax matter federal research base credit goodwill relate diabete divestiture brand prescription drug fee rd charge state local taxis net valuation allowance foreign effective tax rate low statutory rate primarily attributable undistributed earning certain foreign subsidiary consider expect indefinitely reinveste offshore taxis provide approximately billion undistributed earning foreign subsidiary december undistribute earning primarily relate operation ireland puerto rico operate favorable tax grant schedule expire prior undistributed earning repatriate future determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide reform tax law relate foreign earning propose adopt increase taxis reduce result operation cash flow divestiture diabete business result million capital loss tax benefit sale amylin share additional reserve million establish certain transfer pricing matter related tax period goodwill allocate diabete business divestiture brand prescription drug fee research development charge acquisition ipierian deductible tax purpose retroactive reinstatement federal research development credit result additional tax credit million tax insolvency inhibitex result million capital loss tax benefit orphan drug credit include federal research base credit period present annual report defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar millions defer tax asset foreign net operating loss carryforward milestone payment license fee defer income capital loss carryforward federal net operating loss carryforward pension postretirement benefit state net operating loss credit carryforward intercompany profit inventory item federal tax credit carryforward foreign defer tax asset sharebase compensation legal settlement repatriation foreign earning internal transfer intellectual property total defer tax asset valuation allowance net defer tax asset defer tax liability depreciation acquire intangible asset total defer tax liability defer tax asset net recognize asset heldforsale defer income taxis current deferred income taxis noncurrent income taxis payable current liability relate asset heldforsale income taxis payable noncurrent total bristolmyer squibb federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin federal tax credit carryforward expire vary amount begin realization federal tax credit carryforward dependent generating sufficient domesticsource taxable income prior expiration capital loss available million carry carryforward expire amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life december valuation allowance million establish follow item million primarily foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal net operating loss carryforward million federal state capital loss change valuation allowance follow year end december dollar million balance begin year provision utilization foreign currency translation acquisition balance end year income tax payment million million million current tax benefit realize result stock relate compensation credit capital excess par value stock million million million business conduct country world subject tax numerous jurisdiction significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation reconciliation begin end gross unrecognized tax benefit follow year end december dollar million balance begin year gross addition tax position relate current year gross addition tax position relate prior year gross addition tax position assume acquisition gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year annual report additional information unrecognized tax benefit follow year end december dollar millions unrecognized tax benefit recognize impact effective tax rate accrue interest accrue penalty interest expense penalty expensebenefit accrue interest penalty payable unrecognized tax benefit include current noncurrent foreign income taxis payable interest penalty relate unrecognized tax benefit include income tax expense effective january bms adopt update fasb clarify exist guidance presentation unrecognize tax benefit qualifying tax benefit carryforward exist include unrecognized tax benefit present reduction defer tax asset liability noncurrent defer tax asset income tax liability reduce million adoption bms currently examination number tax authority include limited major tax jurisdiction list table propose adjustment tax issue transfer price certain tax credit deductibility certain expense bms estimate reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit primarily settlement related involve payment additional taxis adjustment certain defer taxis andor recognition tax benefit reasonably possible new issue raise tax authority increase unrecognized tax benefit estimate increase reasonably time bms believe adequately provide open tax year tax jurisdiction follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy mexico note earning share year end december amount million share datum net earning attributable bms earning attributable unvested restricted share net earning attributable bms common shareholder earning share basic weightedaverage common share outstanding basic contingently convertible debt common stock equivalent incremental share attributable sharebased compensation plan weightedaverage common share outstanding diluted earning share dilute antidilutive weightedaverage equivalent share stock incentive plans bristolmyers squibb note financial instrument fair value measurement financial instrument include cash cash equivalent marketable security account receivable payable debt instrument derivative change exchange rate interest rate create exposure market risk certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur derivative financial instrument trading purpose financial instrument subject counterparty credit risk consider overall fair value measurement counterparty credit risk monitor ongoing basis mitigate limiting amount outstanding individual counterparty utilize conventional derivative financial instrument enter agreement counterpartie meet high credit quality standard consolidate financial statement materially impact counterparty fail perform accord term agreement collateral require party derivative asset liability position term agreement fair value measurement fair value financial instrument classify follow category level input utilize nonbinde quote price unadjuste active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input level input utilize observable price similar instrument nonbinde quote price identical similar instrument nonactive market observable input corroborate market datum substantially term asset liability instrument include corporate debt security certificate deposit money market fund foreign currency forward contract interest rate swap contract equity fund fix income fund longterm debt additionally certain corporate debt security utilize thirdparty matrix pricing model significant input corroborate market datum substantially term asset equity fix income fund primarily invest publicly trade security value respective net asset value underlie investment significant unfunded commitment restriction redemption relate equity fix income fund december level derivative instrument value london interbank offer rate libor yield curve credit valuation adjustment observable forward foreign exchange rate report date valuation derivative contract fluctuate considerably volatility underlie foreign currency underlie interest rate drive market condition duration contract credit adjustment volatility significant impact valuation interest rate swap contract result change counterparty credit rating credit default swap spread level unobservable input little market datum available fair value write option sell asset certain business note alliance discussion base option pricing methodology consider revenue profitability projection volatility discount rate potential exercise price assumption fair value contingent consideration relate acquisition estimate utilize model consider probability achieve milestone discount rate annual report financial asset liability measure fair value recur basis summarize december december dollar million level level level total level level level total cash cash equivalent money market security marketable security certificate deposit corporate debt security equity fund fix income fund auction rate security ar derivative asset interest rate swap contract foreign currency forward contract equity investment derivative liability interest rate swap contract foreign currency forward contract write option liability contingent consideration liability follow table summarize activity financial asset utilize level fair value measurement write contingent write contingent option consideration ar option consideration dollar million ar liability liability frsa liability liability fair value january addition new alliance unrealize gain sale change fair value fair value december float rate security availableforsale security follow table summarize availableforsale security gross gross unrealize unrealized gain loss amortize accumulate accumulate dollar million cost oci oci fair value december certificate deposit corporate debt security ars equity investment total december certificate deposit corporate debt security ar total bristolmyer squibb availableforsale security include current marketable security million december million december noncurrent availableforsale corporate debt security mature year december ar equity investment million include asset december fair value option financial asset investment equity fix income fund offset change fair value certain employee retirement benefit include current marketable security investment income result change fair value significant qualifying hedge follow summarize fair value outstanding derivative december december dollar million balance sheet location notional fair value notional fair value derivative designate hedge instrument interest rate swap contract asset interest rate swap contract liabilitie foreign currency forward contract prepay expense foreign currency forward contract asset foreign currency forward contract accrue expense foreign currency forward contract liabilitie cash flow hedge foreign currency forward contract primarily utilize hedge forecast intercompany inventory purchase transaction certain foreign currency contract designate cash flow hedge effective portion change fair value report accumulate oci recognize earning hedge item affect earning net gain expect reclassify cost product sell year notional outstanding foreign currency forward contract primarily attribute euro million japanese yen million december fair value foreign currency forward contract attribute japanese yen notional million designate cash flow hedge million include prepay expense december cash flow hedge accounting discontinue forecast transaction long probable occur day originally forecast date hedge long effective assessment determine derivative designate qualifying hedge highly effective offset change cash flow hedge item perform inception quarterly basis earning impact relate discontinued cash flow hedge hedge ineffectiveness significant period present net investment hedge nonus dollar borrowing million million designate hedge foreign currency exposure net investment certain foreign affiliate borrowing designate net investment hedge recognize long term debt effective portion foreign exchange gain loss remeasurement debt recognize foreign currency translation component accumulate oci relate offset long term debt fair value hedge fixedtofloate interest rate swap contract designate fair value hedge interest rate risk management strategy create appropriate balance fix float rate debt contract underlie debt hedge benchmark risk record fair value effective interest rate contract onemonth libor december plus interest rate spread range underlying swap terminate prior maturity fair value basis adjustment underlie debt instrument amortize reduction interest expense remain life debt notional fixedtofloate interest rate swap contract execute million billion notional fixedtofloate interest rate swap contract terminate million generating proceed million include accrue interest million additional contract terminate connection debt redemption debt obligation shortterm borrowing million million december respectively consist primarily bank overdrafts annual report longterm debt current portion longterm debt include december dollar millions principal value euro note note note note euro note note debenture note debenture note note note note debenture mature subtotal adjustment principal value fair value interest rate swap contract unamortize basis adjustment swap termination unamortized bond discount total current portion longterm debta longterm debt include liability relate asset heldforsale december fair value longterm debt million million december respectively estimate base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument float rate convertible senior debenture million redeemable holder par september fundamental change ownership occur callable par time bms debenture current conversion price equal conversion rate share principal subject certain antidilutive adjustment senior unsecured note issue register public offering billion billion interest note pay semiannually note rank equally right payment bmss exist future senior unsecured indebtedness redeemable bms time predetermine redemption price note principal million mature repay substantially billion debt obligation assume acquisition amylin repay include promissory note lilly respect revenue sharing obligation amylin senior note debt redemption debt redemption activity include repayment amylin debt obligation follow dollar million principal carry value redemption price notional interest rate swap contract terminate swap termination proceedspayment total loss bristolmyer squibb interest payment million million million net amount receive interest rate swap contract separate billion fiveyear revolve credit facility maintain syndicate lender facility provide customary term condition financial covenant extendable anniversary date consent lender borrowing outstanding revolve credit facility december financial guarantee provide form standby letter credit performance bond million december standby letter credit issue financial institution support guarantee obligation performance bond issue support range ongoing operating activity include sale product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action significant majority outstanding financial guarantee expire year expect fund note receivable december dollar million trade receivable allowance net trade receivables alliance partner receivables prepaid refundable income taxis miscellaneous receivables receivables nonus receivables sell nonrecourse basis million million million aggregate receivable pharmaceutical wholesaler represent total trade receivables december respectively change allowance bad debt chargeback cash discount follow year end december dollar million balance begin year provision utilization asset heldforsale balance end year note inventory december dollar million finished good work process raw packaging material inventory inventory expect remain onhand year million december million december include asset annual report note property plant equipment december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment property plant equipment relate mount vernon indiana manufacturing facility approximately million december facility expect sell include asset heldforsale period assets available immediate sale present condition note alliance discussion sale diabete business depreciation expense million million million note goodwill intangible asset december estimate dollar million useful life goodwill intangible asset license year develop technology right year capitalize software year inprocess research development iprd gross intangible asset accumulate amortization total intangible asset goodwill million allocate sale diabete business include million present asset heldfor sale december seenote assets heldforsale discussion amortization expense million million million future annual amortization expense intangible asset expect approximately million million million million million million intangible asset impairment charge million billion million iprd impairment charge recognize peginterferon lambda phase iii development treatment hepatitis c virus hcv writeoff require assess potential commercial viability asset estimate fair value assessment consider low likelihood file registration certain market complete revise projection revenue expense significant decline prior project revenue result global introduction oral noninterferon product treat patient hcv alternative use product bm announce discontinued development bm know inx nucleotide polymerase nsb inhibitor phase ii development treatment hcv august decision interest patient safety base rapid thorough ongoing assessment patient phase ii study voluntarily suspend august bm acquire bms acquisition inhibitex february result termination development program billion pretax impairment charge recognize impairment charge million recognize related continued competitive pricing pressure partial writedown fair value develop technology right relate previously acquire non key product bristolmyer squibb note accrue expense december dollar million employee compensation benefit royaltie accrue research development restructure current pension postretirement benefit accrue litigation total accrue expense note sale rebate return accrual reduction trade receivable accrue rebate return liability follow december dollar million chargeback relate government program cash discount reduction trade receivables manage healthcare rebate contract discount medicaid rebate sale return adjustment accrue rebate return note deferred income december dollar million alliance note gain saleleaseback transaction total defer income current portion noncurrent portion alliance include unamortized amount upfront milestone licensing proceed revenue deferral attribute gilead alliance undelivered element diabete business divestiture upfront milestone licensing proceed amortize short contractual right period expect life product defer gain saleleaseback transaction amortize remain lease term relate facility deferral include approximately million invoice product early access program eu portion recognize revenue subject final price negotiation local government amortization defer income million million million deferred income million include liability relate asset heldforsale december seenote asset heldforsale discussion annual report note equity common stock capital treasury stock excess retain noncontrolle par value dollar share million share par value earning share cost interest stock balance january net earning cash dividend declare stock repurchase program employee stock compensation plan comprehensive income attributable noncontrolle interest distribution balance december net earning cash dividend declare stock repurchase program employee stock compensation plan distribution balance december net earning cash dividend declare employee stock compensation plan debt conversion variable interest entity distribution balance december treasury stock recognize cost reacquire share share issue treasury recognize utilize firstin firstout method noncontrolle interest primarily relate plavix avaproavalide partnership sanofi territory cover america net earning attributable noncontrolle interest present net taxis million million million corresponding increase provision income taxis distribution partnership profit sanofi sanofis fund ongoing partnership operation occur routine basis activity include pretax income distribution relate partnership bristolmyers squibb component comprehensive incomeloss follow dollar million pretax tax tax derivative qualify cash flow hedgesa unrealize gain reclassify net earning derivative qualify cash flow hedge pension postretirement benefit actuarial loss amortizationb settlement curtailmentsc pension postretirement benefit availableforsale security unrealize gain realize gainsd availableforsale security foreign currency translation derivative qualify cash flow hedgesa unrealize gain reclassify net earning derivative qualify cash flow hedge pension postretirement benefit actuarial gain amortizationb settlementsc pension postretirement benefit availableforsale security unrealize loss realize gainsd availableforsale security foreign currency translation derivative qualify cash flow hedgesa unrealize gain reclassify net earning derivative qualify cash flow hedge pension postretirement benefit actuarial loss amortizationb settlement curtailmentsc pension postretirement benefit availableforsale security unrealize gain realize gainsd availableforsale security foreign currency translation reclassification net earning derivative qualify effective hedge recognize cost product sell b actuarial gainslosse prior service costcredit amortize cost product sell research development marketing sell administrative expense c pension settlement curtailment recognize incomeexpense realize gain availableforsale security recognize incomeexpense annual report accumulate balance relate component comprehensive incomeloss net taxis follow december dollar million derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation accumulate comprehensive loss note pension postretirement postemployment liabilitie bms sponsor define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal define benefit pension plan bristolmyers squibb retirement income plan cover employee represent approximately consolidated pension plan asset obligation bms contribute minimum require employee retirement income security act erisa plan benefit base primarily participant year credit service final average compensation plan asset consist principally equity fixedincome securities comprehensive medical group life benefit provide substantially retiree elect participate comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory plan asset consist principally equity fixedincome security net periodic benefit costcredit define benefit pension postretirement benefit plan include pension benefit benefit dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service credit amortization net actuarial gainloss curtailment settlement special termination benefit net periodic benefit costcredit september bms fiduciary counselors inc independent fiduciary bristolmyers squibb company retirement income plan enter definitive agreement transfer certain pension asset prudential insurance company america prudential settle approximately billion pension obligation bms purchase group annuity contract prudential december irrevocably assume obligation future annuity payment certain bms retiree transaction change monthly pension benefit receive affected retiree survive beneficiary result pretax settlement charge million pension settlement charge recognize determine annual lump sum payment exceed annual interest service cost certain pension plan include primary pension plan bristolmyer squibb change define benefit postretirement benefit plan obligation asset fund status amount recognize consolidated balance sheet follow pension benefit benefit dollar million benefit obligation begin year service costbenefit earn year interest cost plan participant contribution curtailment settlement plan amendment actuarial gainslosses retiree drug subsidy benefit pay exchange rate gainslosse benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution plan participant contribution settlement retiree drug subsidy benefit pay exchange rate gainslosse fair value plan asset end year fund status assetsliabilitie recognize asset accrue expense pension postretirement liability fund status recognize accumulate comprehensive loss net actuarial gainslosse prior service credit total accumulate benefit obligation define benefit pension plan million million december respectively additional information relate pension plan follow dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset annual report actuarial assumption weightedaverage assumption determine benefit obligation december follow pension benefit benefit discount rate rate compensation increase weightedaverage actuarial assumption determine net periodic benefit creditcost year end december follow pension benefit benefit discount rate expect longterm return plan asset rate compensation increase yield high quality corporate bond match duration benefit obligation determine discount rate citigroup pension discount curve develop discount rate plan expect return plan asset determine expect rate return calculate value asset refer marketrelated value fair value plan asset exceed marketrelated value million december difference assume actual return amortize marketrelated value straightline basis threeyear period factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualize return pension plan follow year year year actuarial gain loss result change actuarial assumption change discount rate revise mortality rate difference assume actual experience difference actual expect return plan asset gain loss amortize life expectancy plan participant plan year expect remain service period plan extent exceed high marketrelated value project benefit obligation respective plan amortization net actuarial loss prior service credit expect approximately million periodic benefit cost credit include cost product sell research development marketing sell administrative expense curtailment settlement special termination benefit include expense assume healthcare cost trend rate december follow healthcare cost trend rate assume year rate cost trend rate assume decline ultimate trend rate year rate reach ultimate trend rate assume healthcare cost trend rate effect amount report healthcare plan onepercentagepoint change assume healthcare cost trend rate material impact service interest cost post retirement benefit obligation bristolmyer squibb plan asset fair value pension postretirement plan asset asset category december follow december december dollar million level level level total level level level total equity security equity fund fix income fund corporate debt security venture capital limit partnership government mortgage back security treasury agency security shortterm investment fund insurance contract event drive hedge fund state municipal bond real estate cash cash equivalent total plan asset fair value investment valuation policy investment class follow level input utilize quote price unadjuste active market accessible measurement date identical asset liability fair value hierarchy give high priority level input instrument include equity security equity fund real estate fund fix income fund publicly trade national security exchange cash cash equivalent cash cash equivalent highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement level input include observable price similar instrument quote price identical similar instrument market active observable input corroborate market datum substantially term asset liabilitie equity fund fix income fund event drive hedge fund shortterm investment fund classify level fair value hierarchy value net asset value share hold year end significant unfunded commitment restriction redemption relate investment value nav december corporate debt security government mortgage back security treasury agency security state municipal bond classify level fair value hierarchy value utilize observable price similar instrument quote price identical similar instrument market active level unobservable input little market datum available venture capital limit partnership classify level fair value hierarchy invest underlying security market value determine pricing model discount cash flow methodology similar technique significant unobservable input valuation methodology include discount rate earn interest taxis depreciation amortization ebitda multiple revenue multiple significant change input result significantly lower high fair value measurement insurance contract interest carry contract value approximate estimate fair value base fair value underlie investment insurance company insurance contract hold certain foreign pension plan follow summarize activity financial asset utilize level fair value measurement venture capital limited insurance dollar million partnership contract total fair value january purchase sale settlement net realize gainslosse unrealize gainslosse fair value december purchase sale settlement net realize gainslosse unrealize gainslosse fair value december annual report investment strategy emphasize equity order achieve higher expect return low expense require cash contribution longterm target asset allocation public equity international global private equity longduration fix income maintain pension plan investment diversify major asset category approximately pension plan equity investment actively manage venture capital limited partnership typically value month lag late available information bms common stock represent plan asset december contribution estimate future benefit payment contribution pension plan million million million expect approximately million estimate annual future benefit payment include lump sum payment range million million year aggregate billion subsequent year period saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match expense attribute define contribution plan million note employee stock benefit plan shareholder approve stock award incentive plan plan replace stock incentive plan share common stock reserve issuance pursuant stock plan option conversion prefer stock million december share available grant active plan million december share issue treasury stock share tender prior year pay purchase price option share previously utilize satisfy withholding tax obligation exercise continue available reserve executive officer key employee grant option purchase common stock market price date option grant option generally exercisable ratably year maximum term year plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price company grant stock option stock appreciation right common stock stock unit grant key employee subject restriction continuous employment generally vest occur ratably year period grant date compensation expense recognize vest period stock unit right receive stock end specify vest period voting right market share unit grant executive vest condition continuous employment vest date payout factor share price award date payout factor share price vest date divide share price award date maximum share price payout factor calculate average closing price grant vest date trading day immediately precede grant vest date vest occur ratably year performance share unit grant executive year cycle grant target number unit subject adjustment base company performance share ultimately issue award grant prior calculate base actual performance compare earning target performance criterion establish beginning year year performance cycle share ultimately issue award grant base actual performance compare earning target performance criterion establish subsequent adjustment company threeyear total shareholder return relative peer group company vest occur anniversary grant date stockbase compensation expense award ultimately expect vest recognize vest period acceleration unvested stock option restrict stock unit connection acquisition amylin result stockbase compensation expense forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate information relate stockbase compensation benefit follow bristolmyer squibb year end december dollar million stock option restrict stock unit market share unit performance share unit amylin stock option restrict stock unit note total stockbase compensation expense income tax benefit stock option restrict stock unit market share unit performance share unit weight number weight number weight number weight number average average average average option exercise price nonveste grantdate nonveste grantdate nonveste grantdate share thousand outstanding share awards fair value award fair value award fair value balance january grant releasedexercised adjustment actual payout forfeitedcancele balance december vest expect vest restrict market performance dollar million stock unit share unit share unit unrecognize compensation cost expect weightedaverage period year compensation cost recognize amount million share datum weightedaverage grant date fair value share restrict stock unit market share unit performance share unit fair value option award vest year stock option restrict stock unit market share unit performance share unit total intrinsic value stock option exercise year fair value award approximate close trading price bms common stock grant date fair value market share unit consider payout formula probability satisfy market condition annual report follow table summarize significant range outstanding exercisable option december amount million share datum option outstanding exercisable number weightedaverage weightedaverage outstanding exercisable remain contractual exercise price aggregate range exercise price thousand life year share intrinsic value aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december note lease annual minimum rental commitment noncancelable operating lease primarily real estate motor vehicle approximately million year aggregate million operate lease expense million million million sublease income material period present note legal proceeding contingency company certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business company recognize accrual contingency probable liability incur loss reasonably estimate matter involve patent infringement antitrust security pricing sale marketing practice environmental commercial health safety matter consumer fraud employment matter product liability insurance coverage legal proceeding material company believe material describe company believe substantial defense matter assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material note company unable assess outcome respective litigation able provide estimate range potential loss furthermore failure enforce patent right likely result substantial decrease respective product revenue generic competition intellectual property baraclude august teva file anda manufacture market generic version baraclude company receive paragraph iv certification letter teva challenge orange bookliste patent baraclude patent patent cover entecavir molecule september company file patent infringement lawsuit district court district delaware delaware district court teva infringement february delaware district court rule company invalidated patent company appeal delaware district court decision june court appeal federal circuit federal court appeal deny company appeal july company file petition en banc rehear entire federal court appeal deny october january company file petition writ certiorari supreme court request court hear appeal federal court appeal decision september teva receive final approval fda generic version entecavir launch product experience rapid significant negative impact net product sale baraclude begin fourth quarter net product sale baraclude million baraclude south korea daewoong pharmaceutical co ltd hanmi pharmaceuticals co ltd initiate separate invalidity action korean intellectual property office korean patent patent patent expire october korean equivalent patent composition matter patent january korean intellectual property tribunal rule patent valid remain risk generic company continue challenge validity patent andor launch generic version baraclude prior october net product sale baraclude south korea million bristolmyers squibb plavix australia previously disclose sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate mg tablets australia genrx subsidiary apotex inc apotex change apotex august apotex file application federal court australia federal court seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september federal court grant sanofis injunction subsidiary company subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidate apotex case trial occur april august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid company sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim stay federal court rule apotex file notice appeal appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim hearing appeal occur february september court hold claim patent invalid november company sanofi apply high court australia high court special leave appeal judgment court march high court deny company sanofis request hear appeal court decision case remand federal court proceeding relate damage seek apotex australian government intervene matter seek damage allege loss experience period injunction place company apotex settle apotex case case dismiss australian government claim pende possible time predict outcome australian government claim impact company plavix canada apotex inc april apotex file impeachment action sanofi federal court canada allege sanofis canadian patent patent invalid june sanofi file defense impeachment action file suit apotex infringement patent trial complete june december federal court canada issue decision patent invalid july federal court appeal reverse federal court canada decision uphold validity patent case remand federal court canada consider damage owe company apotex infringement patent september apotex seek leave appeal decision federal court appeal supreme court canada supreme court canada schedule hear case november company apotex settle case dismiss conclude matter general commercial litigation remain apotex matter relate plavix previously disclose january apotex file lawsuit florida state court broward county allege breach contract relate propose settlement agreement apotex relate pende plavix patent litigation trial hold march jury verdict deliver favor company apotex appeal decision company apotex settle apotex withdraw appeal conclude matter pricing sale promotional practice litigation investigation abilify federal subpoena january company receive subpoena united states attorney office sdny request information relate thing sale marketing abilify possible time assess outcome matter potential impact company abilify state attorney general investigation march company receive letter delaware attorney general office advise multistate coalition investigate certain abilify marketing practice violate respective state consumer protection statute company enter tolling agreement state possible time reasonably assess outcome investigation annual report awp litigation previously disclose company number pharmaceutical manufacturer defendant number private class action suit bring attorney general state action plaintiff allege defendant cause average wholesale price awps product inflate injure government program entity person reimburse prescription drug base awps company remain defendant state attorney general suit pende state court pennsylvania wisconsin begin august company defendant trial commonwealth court pennsylvania commonwealth court bring commonwealth pennsylvania september jury issue verdict company find company liable fraudulent negligent misrepresentation commonwealth court judge issue decision pennsylvania consumer protection claim jury find company liable million enjoin company contribute provision inflate awps company appeal decision pennsylvania supreme court oral argument take place june pennsylvania supreme court vacate commonwealth judge decision remand matter commonwealth court january commonwealth court enter judgment favor company possible commonwealth pennsylvania appeal decision qui tam litigation march company serve unseal qui tam complaint file sale representative california superior court county los angeles california department insurance elect intervene lawsuit complaint allege company pay kickbacks california providers pharmacy violation california insurance frauds prevention act cal in code possible time reasonably assess outcome lawsuit impact company plavix state attorney general lawsuit company certain affiliate sanofi defendant consumer protection andor false advertising action bring state relate sale promotion plavix possible time reasonably assess outcome lawsuit potential impact company product liability litigation company party product liability lawsuit previously disclose addition lawsuit company face unfiled claim involve product plavix previously disclose company certain affiliate sanofi defendant number individual lawsuit state federal court claim personal injury damage allegedly sustain plavix currently claim involve injury plaintiff claim spouse andor beneficiary file state federal court state include california illinois new jersey delaware new york february judicial panel multidistrict litigation grant company sanofis motion establish multidistrict litigation coordinate federal pretrial proceeding plavix product liability relate case new jersey federal court possible time reasonably assess outcome lawsuit potential impact company reglan company number defendant numerous lawsuit behalf approximately plaintiff include injury plaintiff claim personal injury allegedly sustain reglan brand generic drug metoclopramide product indicate gastroesophageal reflux certain gastrointestinal disorder claim spouse andor beneficiary company generic subsidiary apothecon inc distribute metoclopramide tablet manufacture party possible time reasonably assess outcome lawsuit resolution pende lawsuit expect material impact company byetta amylin subsidiary company lilly codefendant product liability litigation relate byetta date separate lawsuit pende behalf active plaintiff include pende settlement include injury plaintiff claim spouse andor beneficiary court company agree principle resolve claim majority case bring individual allege personal injury sustain byetta primarily pancreatic cancer pancreatitis case claim alleged wrongful death majority case pende federal court san diego recently establish multidistrict litigation large contingent case pende coordinated proceed california superior court los angeles amylin product liability insurance cover substantial number claim involve byetta additional liability amylin respect byetta expect share company astrazeneca possible reasonably predict outcome lawsuit claim proceed potential impact company bristolmyer squibb environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include comprehensive environmental response compensation liability act cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate party cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable reasonably estimable company estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party new brunswick facilityenvironmental personal injury lawsuit lawsuit file company new jersey superior court behalf current resident new brunswick new jersey live live adjacent company new brunswick facility complaint allege personal injury result environmental contamination new brunswick facility historical operation site claim medical monitoring portion complaint assert claim allege property damage october new jersey supreme court grant mass tort status case transfer new jersey superior court atlantic county centralize case management purpose october additional case file new jersey superior court remove company united states district court district new jersey accordingly excess case state federal court action june company plaintiff agree settlement finalize december conclude matter north brunswick township board education previously disclose october company contact counsel represent north brunswick nj board education boe site waste material er squibb son disposed fill material contain industrial waste heavy metal excess residential standard discover expansion project north brunswick township high school number neighbor residential property adjacent public park area january new jersey department environmental protection njdep send company information request letter possible waste disposal site company respond march boe township current owner school property park conduct jointly finance soil remediation work ground water investigation work work plan approve njdep ask company contribute cost company actively monitor cleanup project include cost date school board township assert claim company instead company local entity negotiate agreement attempt resolve matter informal mean avoid litigation central component agreement provision company interim funding help defray cleanup cost assure work interrupt company transmit interim funding payment december november party commence mediation late effort successful party move bind allocation process party expect conduct fact expert discovery follow formal evidentiary hearing write argument addition september township boe file suit party allege contribute waste material site litigation settle party company currently believe responsible additional amount interim payment total million transmit additional possible loss expect material proceeding sec germany investigation october sec inform company begin formal inquiry activity certain company german pharmaceutical subsidiary employee andor agent sec inquiry encompass matter investigation german prosecutor munich germany resolve company understand inquiry concern potential violation foreign corrupt practice act fcpa company cooperate sec fcpa investigation march company receive subpoena sec issue connection investigation fcpa primarily relate sale marketing practice country company cooperate sec department justice investigation matter particular company investigate certain sale marketing practice china possible time assess outcome matter potential impact company annual report note select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earning net earningsloss attributable noncontrolle interest bms earning share basica earning share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debt equity dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earning net earningsloss attributable noncontrolle interest bms earning share basica earning share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debtc equity earning share quarter add amount year period compute discrete basis b marketable security include current noncurrent asset c include current portion longterm debt bristolmyer squibb follow specify item affect comparability result second fourth dollar million quarter quarter quarter quarter year cost product solda additional year brand prescription drug fee process standardization implementation cost marketing sell administrative upfront milestone payment iprd impairment research development provision restructure gain sale product line business asset pension curtailment settlement special termination benefit acquisition alliance relate itemsb litigation chargesrecoverie loss debt redemption outlicense intangible asset impairment upfront milestone licensing receipt incomeexpense increasedecrease pretax income income tax item specify tax chargec income taxis increasedecrease net earning specify item cost product sell accelerate depreciation asset impairment shutdown cost b include million additional year brand prescription drug fee quarter c specify tax charge relate transfer pricing matter annual report second fourth dollar million quarter quarter quarter quarter year accelerate depreciation asset impairment shutdown cost amortization acquire amylin intangible asset amortization amylin alliance proceed amortization amylin inventory adjustment cost product sell marketing selling administrativea research developmentb provision restructure pension settlement acquisition alliance relate item litigation recovery upfront milestone licensing receipt incomeexpense increase pretax income income tax item increase net earning specify item marketing sell administrative process standardization implementation cost b specify item research development upfront milestone licensing payment bristolmyers squibb report management management responsibility financial statement management responsible preparation integrity financial information present annual report accompany consolidated financial statement prepare conformity united states generally accept accounting principle apply certain estimate judgment require management opinion consolidated financial statement present fairly company financial position result operation cash flow audit committee board director meet regularly internal auditor deloitte touche llp dt company independent register accounting firm management review account internal control structure financial reporting matter internal auditor dt free access audit committee set forth company standard business conduct ethic company firmly commit adhere high standard moral ethical behavior business activity management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include annual report issue report management assessment effectiveness company internal control financial reporting appear annual report lamberto andreotti chief executive officer charle bancroft chief financial officer february annual report control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule ae base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report issue report effectiveness company internal control financial reporting december include change internal control financial reporting change company internal control financial reporting quarter end december materially affect reasonable likely materially affect company internal control financial reporting information bristolmyer squibb report independent register public accounting firm board director shareholder bristolmyers squibb company audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income cash flow year period end december financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position bristolmyer squibb company subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america audit accordance standard public company accounting oversight board united states company internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting parsippany new jersey february annual report report independent register public accounting firm board director shareholder bristolmyers squibb company audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion company maintain material respect effective internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission audit accordance standard public company accounting oversight board united states consolidated financial statement year end december company report date february express unqualified opinion consolidated financial statement parsippany new jersey february bristolmyers squibb performance graph follow performance graph compare performance bristolmyer squibb period indicate performance standard poor stock index sp average performance group consist peer corporation line ofbusiness basis corporation make peer group abbvie inc amgen inc astrazeneca plc biogen idec inc celgene corp eli lilly company gilead sciences inc glaxosmithkline johnson johnson merck co inc novartis ag pfizer inc roche holding ltd sanofi total return index reflect reinveste dividend weight beginningperiod market capitalization report time period bristolmyers squibb sp index peer group assume invest bristolmyer squibb common stock sp index peer group value december specify year assume dividend reinveste annual report fiveyear financial summary amount million share datum income statement dataa total revenue continue operation net earning net earning attributable noncontrolle interest bms net earning common share attributable bms basic diluted average common share outstanding basic diluted cash dividend pay bms common prefer stock cash dividend declare common share financial position datum december cash cash equivalent marketable securitiesb total asset longterm debtc equity discussion item affect comparability result year item management discussion analysis financial condition result operationsnongaap financial measure b include current noncurrent marketable security c include current portion longterm debt bristolmyer squibb annual report bristolmyer squibb leadership board director james cornelius alan j lacy chairman bristolmyers squibb chairman chief executive officer sears roebuck co ab lamberto andreotti chief executive officer thomas j lynch jr md chairmandesignate bristolmyers squibb director yale cancer center physicianinchief smilow cancer giovanni caforio md hospital yalenew bd chief operating officer ceodesignate bristolmyer squibb dinesh c paliwal executive chairman president lewis b campbell chief executive officer retire chairman harman international industries inc ab chief executive officer textron inc navistar international corporation bc vicki l sato phd professor management practice laurie h glimcher md harvard business school cd stephen suzanne weiss dean cornell medical college cornell gerald l storch university provost medical affair ad chief executive officer hudson bay company michael grobstein nonexecutive chairman supervalu inc ac retired vice chairman ernst young llp ac togo west jr chairman tli leadership group bc audit committee b committee director corporate governance c compensation management development committee science technology committee bristolmyers squibb annual report senior management team lamberto andreotti ann powell judge chief executive officer senior vice president chairmandesignate global human resource charle bancroft sandra leung executive vice president executive vice president chief financial officer general counsel corporate secretary giovanni caforio md samuel moe chief operating officer senior vice president ceodesignate strategic planning analysis francis cuss mb bchir frcp anne nielsen executive vice president senior vice president chief scientific officer chief compliance ethic officer john elicker lou schmukler senior vice president president global manufacturing supply public affair investor relation paul von autenrie senior vice president enterprise service chief information officer bristolmyers squibb annual report stockholder information common stock product name ticker symbol bmy free copy company annual company program new york stock exchange report fiscal year global product company program end december contact name appear italic annual meeting stockholder corporate secretary refer register tuesday bristolmyers squibb company approve trademark bristolmyers squibb company park avenue specifically note scudder mill road new york ny abilify trademark otsuka plainsboro nj available pharmaceutical co ltd investorbmscom stockholder service atripla trademark bristolmyer recent certification squibb gilead sciences llc inquiry concern stockholder company chief executive officer chief account stock transfer matter financial officer pursuant section avaproavalide know eu include address change elimination sarbanesoxley act file aprovelkarvea plavix duplicate mailing shareowner exhibit company trademark sanofi service plus plansm direct company file new company transfer agent york stock exchange recent byetta bydureon symlin trade registrar annual ceo certification require mark amylin pharmaceuticals llc section aa new york stock astrazeneca pharmaceutical lp wells fargo shareowner services exchange list company manual erbitux trademark imclone llc centre pointe curve suite whollyowne subsidiary eli lilly mendota height mn additional information company wwwshareowneronlinecom information follow subject farxiga xigduo onglyza kombiglyze available wwwbmscom trademarks astrazeneca ab bristolmyers squibb foundation outside clinical trial gleevec trademark novartis ag telecommunication relay service hear impair compliance ethic norvir trademark abbvie inc call telephone number diversity workforce statistics reglan trademark anip patient assistance program acquisition company shareowner service plus plansm policy advocacy engagement truvada tybost trademark shareowner service plus plansm political contribution gilead sciences inc design longterm investor wish sustainabilityenvironmental program brand name product build share ownership company common stock time par annual report contain certain italicize letter asterisk ticipate plan register forwardlooke information register trademark bms holder company common stock mean private security litigation andor subsidiary companys common reform act forward stock participant look statement base current making initial purchase expectation involve inherent risk plan plan feature dividend uncertainty cause actual reinvestment optional cash purchase come result differ materially share safekeeping share sale current expectation transfer bristolmyer squibb company financial review discussion appoint wells fargo shareowner description risk uncertainty service administrator plan company undertake obligation plan sponsor administer publicly update forwardlooke state bristolmyer squibb company ment result new informa tion future event shareowner service plus plan service mark wells fargo shareowner services n work year ago tony holladay meridian idaho begin trouble sleep usual reason right hand turn big round ball not finger knuckle recall wrong eventually lose dexterity hand start hard time walk move bad pain tony long enjoy outdoors not lifestyle want curl little ball leave take aspirin day pain s see doctor diagnose rheumatoid arthritis ra tony remember come home crying not want burden family say decide silly stand say time start variety treatment twoto threeyear period switch orencia iv abatacept return abide interest make stain glass window kaleidoscope involve lot glass cutting require lot dexterity finger fine motion hand say leave little piece window tony pain free year m long burden family m able thing not able year say today doctor not use elevator run flight stair feel good great life great life produce bristolmyer squibb public affairs department copyright bristolmyers squibb company right reservedbristolmyers squibb company park avenue new york ny wwwbmscom